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Mitochondria perform different tasks in diverse cell types. For instance, mitochondria control differentiation of immune and stem cells1,2. Similarly, in the nervous sys-
tem, mitochondria regulate neurite branching and regeneration3, as 
well as synaptic strength, stability and signaling4. Although some 
of these cell-type-specific functions are achieved by modulating the 
well-characterized metabolic roles of mitochondria, less-expected 
functions emerge, for example, in immune or redox signaling5,6, and 
likely many more remain elusive.
Bulk mitochondrial proteomes vary between tissues7. Nevertheless, 
it remains unclear to what degree such diversity reflects tissue-specific 
global differences or variations in cellular composition. Moreover, 
genes that encode mitochondrial proteins are differentially expressed 
among tissues, cell types and even cell compartments8, but how much 
such transcriptional diversity results in mitochondrial proteome vari-
ability has not been resolved. Indeed, although the extrapolation of 
proteomics data from transcriptomes is generally problematic9, the 
mitochondrial proteome is uniquely complex, especially in cells of 
extended geometry, such as neurons3. Hence in these complex cell 
types it is crucial to directly measure proteomic variability. Moreover, 
it is important to obtain functional mitochondria from the respective 
cell of interest to test any resulting predictions.
Here, we describe an approach that allows isolation of functional 
mitochondria from essentially any cell type. This approach is based 
on a MitoTag mouse, which faithfully expresses an outer mitochon-
drial membrane (OMM)-targeted green fluorescent protein (GFP) 
in a Cre recombinase (Cre)-dependent manner. This innocuous and 
efficient epitope allows capturing of cell-type-specific mitochon-
dria. We highlight the power of our approach by comparing neural 
mitochondria of the three major cell populations from the cerebel-
lum. Thus, we (1) provide a systematic profiling of cell-type-specific 
variability among mitochondrial proteomes in situ and (2) identify 
numerous cell-type-specific mitochondrial markers that are suit-
able to characterize cell-type-specific mitochondria in the healthy 
and diseased mouse and human brain. On this basis, we predict and 
prove differences between mitochondria from different cerebellar 
cell types regrading (3) beta-oxidation, (4) calcium buffering via the 
mitochondrial calcium uniporter (Mcu) and (5) organelle contacts 
mediated by the tether regulator of microtubule dynamics protein 
3 (Rmdn3).
Results
MitoTag mice innocuously tag cell-type-specific mitochondria 
in vivo. Previous work established tagging of macromolecular struc-
tures such as ribosomes to explore cell-type-specific mRNA trans-
lation profiles in situ10. This approach recently has been extended 
to organelles, for example, to explore mitochondrial11 and lyso-
somal12 metabolomes in vitro or organellar DNA in invertebrates13, 
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or to correlate transcriptional and epigenetic signatures14. To study 
mitochondrial diversity among cell types in situ using mitochondria 
that are directly derived from their tissue context, we generated a 
reporter line, named MitoTag mouse (Fig. 1a). MitoTag mice har-
bor in their Rosa26 locus a floxed ‘stop’ expression cassette, which 
drives expression of GFP targeted to the OMM in a Cre-dependent 
manner (GFP–OMM). To achieve GFP–OMM expression in diverse 
cell types of the CNS, we crossed MitoTag mice to different Cre-
driver lines (Supplementary Fig. 1) or neonatally injected them with 
adeno-associated virus to deliver Cre in a cell-type-specific manner 
(Supplementary Fig. 1f). Initial characterization was performed on: 
(1) Emx1:Cre crossed to MitoTag mice (abbreviated as Emx1:Cre/
GFP–OMM), where the great majority of forebrain neurons 
and glia contained GFP–OMM-tagged mitochondria (Fig. 1b and 
Supplementary Fig. 1a); and (2) ChAT:Cre/GFP–OMM mice, 
where mitochondria in cholinergic neurons, including motor neu-
rons, are tagged (ChAT, choline acetyltransferase; Supplementary 
Fig. 1b). First, we confirmed mitochondrial localization of GFP–
OMM by counterstaining Emx1:Cre/GFP–OMM cortex with the 
endogenous inner mitochondrial membrane protein cytochrome 
c oxidase subunit 4 isoform 1 (Cox4i1; Fig. 1c). We corroborated 
OMM localization by expansion microscopy in Emx1:Cre/GFP–
OMMxThy1:mito-RFP mice (Fig. 1d), which additionally express 
matrix-localized red fluorescent protein (mito-RFP) in neurons. 
Second, we used ChAT:Cre/GFP–OMM mice to rule out adverse 
transgene effects on mitochondrial and cellular health in motor 
neurons by measuring mitochondrial transport and shape, as well 
as neuromuscular synapse morphology (Supplementary Fig. 2a–d). 
Finally, the crude mitochondrial fraction (CMF) from Emx1:Cre/
GFP–OMM cortex showed unchanged oxygen consumption rates 
(OCRs) compared with controls (Supplementary Fig. 2e).
To isolate GFP–OMM-tagged mitochondria, we optimized an 
immunocapture protocol using anti-GFP magnetic microbeads (IC 
GFP; Fig. 1e). This method is well established for mitochondria 
based on anti-Tom22 microbeads15 but recently has been expanded 
to neoantigens11,13. Indeed, for Emx1:Cre/GFP–OMM cortex, west-
ern blot analysis corroborated efficient mitochondrial enrichment 
via IC GFP (Supplementary Fig. 3a). Using electron microscopy, we 
found that the majority of GFP-captured objects were isolated mito-
chondria with well-preserved ultrastructure, in contrast with the 
CMF, which contained synaptosome-enclosed mitochondria and 
myelin debris (Fig. 1f). Moreover, mitochondria that were immu-
nocaptured from either control cortex (Cre− MitoTag mice; IC Tom 
using anti-Tom22 microbeads) or Emx1:Cre/GFP–OMM cortex 
(~74% GFP–OMM-tagged mitochondria; Supplementary Fig. 4b) 
did not differ in respiratory capacity (Fig. 1g).
MitoTag mice allow isolation of cell-type-specific mitochondria 
from complex tissues in situ. A major concern in enriching cell-
type-specific mitochondria from tissue is that during the isolation, 
mitochondria from different cells could merge by clumping or 
fusion16. Indeed, we observed that once we pelleted mitochondria 
by centrifugation, separation via IC GFP was impaired. Therefore, 
to determine the selectivity of our immunocapture, we devised 
‘spike-in’ experiments with mitochondria carrying mito-RFP. 
First, we used an ex vivo mixing experiment where cortexes from 
Emx1:Cre/GFP–OMM mice and Thy1:mito-RFP mice were mixed 
one to one (50:50%) and subjected to immunocapture (Fig. 2a(i)). 
Using western blot analysis, we observed that IC Tom recovered 
the initial GFP–OMM/mito-RFP ratio of the CMF, whereas tagged 
mitochondria were selectively enriched with IC GFP (GFP–OMM: 
4.7-fold compared with IC Tom; Fig. 2b,c and Supplementary Fig. 
5a). We mimicked cell populations with various abundance by 
mixing the postnuclear fractions from Emx1:Cre/GFP–OMM and 
Thy1:mito-RFP cortex in different ratios, and found that the isola-
tion efficacy stayed stable down to dilutions of 1:20 (Supplementary 
Fig. 5b,c). Throughout, we detected ∼5% of mito-RFP in IC GFP. 
To corroborate this experiment in vivo, we used ChAT:Cre/GFP–
OMM cortex, where less than 1% of mitochondria are tagged 
(Supplementary Fig. 4b), representing a low abundant population of 
exclusively axonal mitochondria from cholinergic neurons. Still, the 
immunocapture allowed us to enrich substantial amounts of mito-
chondria (Supplementary Fig. 5d). Finally, to corroborate enrich-
ment of tagged mitochondria from tissue, we immunocaptured 
astrocytic mitochondria from Gfap:Cre/GFP–OMMxThy1:mito-
RFP cortex (Fig. 2a(ii)). This tissue contained ~29% GFP–OMM-
labeled mitochondria from astrocytes and 63% mito-RFP-positive 
neuronal mitochondria (Supplementary Fig. 4b). Here, GFP–OMM 
was enriched by 7.4-fold compared with IC Tom from immediately 
adjacent cells (Fig. 2d).
Label-free proteomics demonstrates mitochondrial diversity 
in the adult cerebellum. The cerebellum is composed of various 
well-characterized cell types, for which specific Cre-driver lines 
are available, and it is prone to mitochondrial dysfunction. Thus, 
we used the cerebellum as a proof-of-concept to test whether our 
MitoTag approach could resolve cellular diversity of the mito-
chondrial proteome in  situ. First, we generated MitoTag lines for 
the following cell types (Fig. 3a and Supplementary Fig. 1c–e): (1) 
Purkinje cells (PC), the major inhibitory neuron of the cerebellum, 
via L7:Cre; (2) granule cells (GC), the most abundant excitatory 
neuron, via Gabra6:Cre; and (3) astrocytes (A) via Gfap:Cre. Next, 
we developed a label-free proteomic workflow for the comparison 
of mitochondrial proteomes that involved immunocapture of cell-
type-specific mitochondria (IC GFP) and total tissue mitochondria 
(IC Tom) per biological replicate (n ≥ 5 mice; Supplementary Fig. 
6). IC Tom provided an ‘average mitochondrial proteome’ from the 
cerebellum, thereby correcting for variation among experiments 
and mouse cohorts. In this background proteome, we quantified 
3,718 proteins, which we compared with reference proteomics data-
sets from mouse cerebellar mitochondria7 and from whole cerebel-
lum17, revealing a coverage of 68% MitoCarta18 annotated proteins 
(Supplementary Fig. 3b). Moreover, intensity-based absolute quan-
tification (iBAQ) demonstrated strong enrichment of mitochondrial 
proteins over nonmitochondrial proteins (for example, 6.51-fold for 
immunocaptures from cerebellum; Supplementary Fig. 3c), despite 
our deliberate choice of a ‘conservative’ isolation approach with the 
aim to include transiently OMM-associated proteins for discovery 
and preserve organelle functionality (see Methods). In comparison, 
our proteome obtained from whole cerebellum revealed that mito-
chondrial proteins were 2.64-fold more abundant than nonmito-
chondrial proteins. In contrast, a published proteome of cerebellar 
mitochondria purified by Percoll7 uncovered a 6.57-fold increased 
abundance of mitochondrial over nonmitochondrial proteins, 
matching our own enrichment with immunocapture. Indeed, 56.5% 
of peptides accounted for mitochondrial proteins in immunocap-
tures (Supplementary Fig. 3d). Importantly, mitochondrial proteins 
showed more prominent abundance changes than nonmitochon-
drial proteins. For example, 23.1% of mitochondrial annotated pro-
teins from PC showed a significant abundance change (IC GFP/IC 
Tom ratio >1.5 or <0.67; P < 0.05), whereas only 4.0% of nonmito-
chondrial proteins were significantly changed, suggesting that most 
of the latter are not specifically captured.
In total, >85% of identified proteins were shared among all three 
cell types (Supplementary Fig. 6). We identified 196 candidates with 
differential expression (log2 fold change (FC) ≥ │1│ between cell 
types), of which 89.8% are mitochondrial annotated. Of these, 18, 
51 and 114 were exclusively enriched in one cell type (Fig. 3b and 
Supplementary Fig. 7d). An additional 13 proteins showed shared 
enrichment in two cell types. When we compared proteins from 
astrocytic mitochondria against either mitochondria from GC (y axis; 
Fig. 3c and Supplementary Fig. 7a) or PC (x axis; Fig. 3c and 
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Fig. 1 | MitoTag mice allow isolation of intact and functional mitochondria from cells in situ. a, GFP–OMM insertion into the mouse Rosa26 locus.  
b, Absence of expression in stopped MitoTag cortex (left and middle; Cre−), but GFP–OMM (green) in neural cells from Emx1:Cre/GFP–OMM mice (right; 
Cre+). Nuclear counterstain (Nuc; white) is shown in the left panel. c, Immunostaining of the Emx1:Cre/GFP–OMM cerebral cortex for Cox4i1 (magenta) 
confirms mitochondrial localization of GFP–OMM (arrowheads). d, Expansion microscopy of Emx1:Cre/GFP–OMMxThy1:mito-RFP cerebral cortex shows 
localization of GFP–OMM in the OMM (green) surrounding mito-RFP (magenta), which is localized to the mitochondrial matrix of a large subset of 
neurons. e, Immunocapture of GFP–OMM-tagged mitochondria (IC GFP). f, Electron micrographs comparing the CMF from Emx1:Cre/GFP–OMM cortex 
with IC GFP. Note the free mitochondria (*) and synaptosome-enclosed mitochondria (#) found in CMF (top) and free, intact mitochondria (X, +) with 
microbeads (black dots in micrograph; bottom). g, Bioenergetic parameters derived from oxygen consumption measurements in the presence of pyruvate–
malate (left) and succinate–rotenone (right) as substrates for immunocaptured mitochondria. Mitochondria were immunocaptured from Emx1:Cre−/
GFP–OMM or Emx1:Cre+/GFP–OMM cortex using Tom22 (pan-mitochondrial, IC Tom) or GFP–OMM (cell-type-specific mitochondria, IC GFP) as bait 
(no significant differences observed with one-way ANOVA with post hoc testing; n ≥ 4 mice from at least three independent experiments). Dot plot: 
mean ± s.e.m. Images show representative results from n = 5 (b,c) and n = 2 (d,f) independent experiments. Scale bars: 100 µm (b); 5 µm (c,d and insets 
in d; note that for d, an estimated expansion factor of ~2–3 applies); 500 nm (f) (250 nm in insets). CE, coupling efficiency; CMF, crude mitochondrial 
fraction; e1/2, exon 1/2; Nuc, nuclear counterstain; P, promoter; RCR, respiratory capacity ratio; SCR, spare capacity ratio.
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Supplementary Fig. 7b), we detected a separation in protein compo-
sition of neuronal mitochondria from glial mitochondria. Equally, 
the KEGG pathway and GOTerm process analysis (Supplementary 
Fig. 7e,f) confirmed differential specializations of neuronal (for 
example, ubiquinone biosynthesis) versus astrocytic mitochondria 
(for example, lipid metabolism). In contrast, other mitochondrial 
protein pathways, namely respiratory chain components, protein 
import and translation, tricarboxylic acid cycle showed no system-
atic differences, pointing to a conserved core of the mitochondrial 
proteome (Supplementary Fig. 8).
Cell-type-specific mitochondrial markers confirm mitochon-
drial diversity. We selected 28 proteins that our proteomics data 
predicted as cell type enriched for further validation based on litera-
ture and antibody availability, in addition to Cox4i1 as a ubiquitous 
mitochondrial marker and syntaphilin (Snph) as a known19 neu-
ronal marker (which was not significantly enriched in the profiled 
cell types). Using immunofluorescence staining, we confirmed in 
all testable cases (21/28) our predicted cell-type-enriched expres-
sion and subcellular localization in mitochondria (Fig. 3d–f and 
Supplementary Fig. 9). Furthermore, we confirmed the specific fold 



































































































Fig. 2 | Immunocapture from MitoTag mice enriches cell-type-specific mitochondria without mitochondrial cross-contamination from other cells.  
a, ‘Spike-in’ experiments to demonstrate enrichment of GFP–OMM-tagged mitochondria from other mitochondria (mito-RFP). Using the cortex, we mixed 
two mitochondrial populations (GFP–OMM and mito-RFP) either ex vivo on the tissue level (i) or in vivo (ii) by breeding Gfap:Cre/GFP–OMMxThy1:mito-
RFP mice. b,c, Enrichment of GFP–OMM-labeled mitochondria after immunocapture via GFP–OMM (IC GFP), but not via Tom22 (IC Tom), from the ex 
vivo mixing experiment (schematic in a(i)). The cortexes from Emx1:Cre/GFP–OMM (c, top micrograph for tissue expression; GFP–OMM, green; Nuc, 
white) and from Thy1:mito-RFP (c, bottom micrograph; mito-RFP, red) were mixed in a 50:50 ratio before lysate generation (b; mix, orange). b, Western 
blot probing for GFP–OMM, mito-RFP and mitochondrial proteins (Tomm20, OMM; ATP5a, inner mitochondrial membrane (IMM); CypD, matrix). Note 
enrichment of GFP–OMM via IC GFP from pure Emx1:Cre/GFP–OMM tissue (lysate: GFP–OMM) and the absence of any mitochondrial isolation from 
pure mito-RFP tissue (lysate: mito-RFP). Representative results from n = 2 independent experiments. Mixing condition is quantified in c. c, Quantification 
of ex vivo mixing experiment (a(i)) comparing isolations with initial CMF (GFP–OMM, green bar: P = 0.0002; mito-RFP, red bar: P = 0.037, one-tailed ratio-
paired t-test; n = 5 isolations). Densitometry is normalized to mitochondrial content. Dot plot: mean ± s.e.m. d, In vivo ‘spike-in’ experiment (a(ii)) using 
cortex from Gfap:Cre/GFP–OMMxThy1:mito-RFP mice (micrograph for tissue expression) as starting material with an ~31:69 ratio (ratio of GFP–OMM to 
mito-RFP mitochondria excluding nonlabeled organelles; see Supplementary Fig. 4b). Graph shows quantification from western blot analysis comparing 
isolations with initial CMF (GFP–OMM, P = 0.0002, one-tailed ratio-paired t-test; n = 5 isolations). Dot plot: mean ± s.e.m. Scale bars: 20 µm (c,d). CMF, 
crude mitochondrial fraction; FC, fold change; IC, immunocapture; Nuc, nuclear counterstain. 




























































All proteins FDR ≤ 0.05
MitoCarta























log2 FC (PC/A)log2 FC (GC/A)
A versus GC





























Fig. 3 | Proteomic profiling of cell-type-specific mitochondria in the adult mouse cerebellum. a, GFP–OMM expression patterns (green) and Cox4i1 
staining (pan-mitochondrial; magenta) in the investigated cerebellar cell types: astrocytes–Bergmann glia (left; Gfap:Cre), excitatory GC (middle; 
Gabra6:Cre) and inhibitory PC (right; L7:Cre). Schematics show cell morphology and anatomic position within the cerebellum. Details show partial 
colocalization of cell-type-specific GFP–OMM with Cox4i1. b, Venn diagram depicting candidates (n = 196) with cell-type-specific enrichment  
obtained by proteomics (FC ≥ │1│ from the pairwise comparison between cell types) and their subcellular localization (Cyto, cytoplasmic; ER, 
endoplasmic reticulum; Mito, mitochondrial; Nonmito, nonmitochondrial; Nuc, nuclear; Pex, peroxisomal; PM, plasma membrane; and other).  
c, Comparison of cell-type-specific mitochondrial proteomes between cell types (top: volcano plots comparing GC/A (left) and PC/A (right); two-tailed 
t-test, FDR ≤ 0.05, 500 randomizations, n ≥ 3 quantifications) and among cell types (bottom: scatterplot of proteins merging the previous comparison 
between cell types (FDR ≤ 0.05 in at least one comparison); x axis, PC/A; y axis, GC/A). In volcano plots, dark gray circles represent proteins with 
FDR ≤ 0.05. In the scatterplot, all circles represent proteins from volcano plots with FDR ≤ 0.05; black circles, MitoCarta annotated proteins; open 
magenta circles, candidates shown in a and d–f. FC, fold change. d–f, Validation of candidates by immunofluorescence staining in cerebellum. 
Candidates show prominent colocalization with cell-type-specific GFP–OMM (green), confirming the proteomics data (see c) of PC (d), GC (e) and 
astrocytes (f). Note the pan-neuronal patterns of Ldhd, Gls2 and Got2 (d,e) and the pinceau-like organization of Snph, likely in Basket axon collaterals 
around PC soma. GFP–OMM is driven by the Cre-driver lines introduced in a. Arrowhead, nuclear signal. Images in a and d–f show representative  
results from n = 3 independent experiments. Scale bars: 20 µm (a,d–f) (10 µm in insets). A, astrocyte, GCL, ganule cell layer; ML, molecular layer; PCL, 
Purkinje cell layer.
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changes obtained by mass spectrometry using western blot quanti-
fication for a subset of candidates (Supplementary Fig. 10). In seven 
cases, no confirmation was achieved because of antibody quality. 
Some of the validated candidates, especially in astrocytes (Fig. 3f), 
represent mitochondrial proteins with previous cell-type-specific 
annotation, such as glycine dehydrogenase (Gldc)20, sideroflexin-5 
(Sfxn5)21 and monoamine-decarboxylase B (MaoB), which is tar-
geted in positron-emission tomography as an astrocyte tracer22. 
Notably, the astrocytic mitochondrial proteome contained a sub-
stantial enrichment of peroxisomal proteins (Supplementary Figs. 
7e,f and 9c), some of which are known to have dual targeting (for 
example, catalase)23 or tether to mitochondria (for example, Eci2 
(ref. 24) and Pex11b (ref. 25)). In neurons, we expected to identify 
Snph, a protein involved in regulating mitochondrial distribution 
and generally believed to be enriched on axonal mitochondria19. 
Indeed, in line with our proteomics, we confirmed only weak sig-
nals in PC and GC mitochondria; however, we observed prominent 
mitochondrial labeling in Basket axon collaterals synapsing onto 
PC somata, hence forming the pinceau organization (Fig. 3d and 
Supplementary Fig. 9a). In some instances, differentially expressed 
paralogs were detected between cell types (for example, adenylate 
kinase 4 (Ak4) versus Ak3; glutaminase (Gls) versus Gls2; Fig. 3e,f). 
In addition, we observed two forms for Ociad2, a non-MitoCarta 
protein dually assigned to mitochondria and endosomes in a recent 
publication26. A C-terminal antibody confirmed our proteomic pre-
diction of enrichment in PC mitochondria, whereas an amino-ter-
minal antibody showed enrichment in GC (Supplementary Fig. 11). 
Surprisingly, we identified cell-type-specific enrichment of mito-
chondrial proteins for which we expected ubiquitous expression, 
for example, the mitochondrial calcium uniporter (Mcu)27,28 and 
its regulators in GC. Similarly, Rmdn3 (also known as PTPIP51), 
a tether involved in calcium handling29 and lipid transfer30 between 
the endoplasmic reticulum (ER) and mitochondria, was enriched 
in PC. Altogether, our validated group of cell-type-specific mito-
chondrial proteins supports the notion that, depending on cell type, 
mitochondria play diverse roles in metabolism, calcium handling 
and organelle communication.
Markers reveal cell-type-specific mitochondrial changes in mouse 
and human pathology. Next, we wanted to explore whether the 
identified markers could be used to analyze cell-type-specific mito-
chondria in human pathology. To generalize their applicability, we 
tested a subset in two other CNS regions, cortex and spinal cord. 
Indeed, we observed the characteristic pattern of neuronal and 
astrocytic mitochondria coinciding with cell-type-specific labeling 
(Fig. 4a and Supplementary Fig. 12). We then applied these mark-
ers to tissue from mouse models of Alzheimer’s disease (APPPS1 
mice) and amyotrophic lateral sclerosis (SODG93A mice), condi-
tions for which mitochondrial contributions have previously been 
claimed4, but the differential roles of neurons versus astrocytes are 
still debated31. Indeed, the introduced markers showed pathologi-
cal changes in mitochondrial distribution and shape. For example, 
they revealed reduced density of neuronal, and to a lesser degree 
glial, mitochondria around amyloid plaques in the APPPS1 mouse 
model (Fig. 4b and Supplementary Fig. 13a,b). Similarly, we found 
pronounced changes in neuronal mitochondria in 3-month-old 
SODG93A mice, which were not detectable in astrocytes (Fig. 4d and 
Supplementary Fig. 14a). Importantly, we confirmed the expres-
sion pattern of our mitochondrial markers in human tissues (Fig. 4a  
and Supplementary Fig. 15) and performed immunofluorescence 
stainings on human cortex of patients with Alzheimer’s disease and 
human spinal cord affected by amyotrophic lateral sclerosis (Fig. 4c,e 
and Supplementary Figs. 13c and 14b). These stainings corroborated 
the changes observed in animal models, thus confirming that the 
MitoTag profiling used in this study identified suitable markers to 
study cell-type-specific mitochondrial pathology in human disease.
Fatty acids are more efficiently metabolized by astrocytic than 
neuronal mitochondria. To further explore mitochondrial diver-
sity on the functional level, we performed pathway analysis between 
neuronal and astrocytic mitochondria, and detected an enrichment 
of enzymes involved in mitochondrial beta-oxidation (Fig. 5a and 
Supplementary Fig. 7e). However, the brain is often assumed to rely 
on glucose and lactate for energy production, rather than lipids32. 
Still, neural cells appear to respire on fatty acids under certain condi-
tions33 with important functional implications, for example, in stem 
cell proliferation34. Despite this, and even though previous bioinfor-
matics analysis has predicted astrocytic beta-oxidation35, it remains 
controversial whether under steady-state conditions neural cells are 
fully equipped to perform long-chain fatty acids respiration. Guided 
by our proteomic profiling, we addressed this question by first con-
firming the astrocytic enrichment of two enzymes involved in beta-
oxidation by immunofluorescence staining, short-chain-specific 
acyl-coenzyme A dehydrogenase (Acads; Fig. 3f and Supplementary 
Fig. 9d) and carnitine palmitoyltransferase 1a (Cpt1a; Fig. 5b), a 
rate-limiting enzyme in long-chain fatty acids oxidation. Second, 
we used our approach to compare oxygen consumption rates of 
in  situ isolated cell-type-specific mitochondria on the C16–fatty 
acid, palmitoyl–carnitine (Fig. 5c and Supplementary Fig. 16). We 
chose a substrate that is preferentially metabolized in mitochondria 
as a result of its carbon chain length and carnitine pre-conjugation, 
because astrocytic mitochondria appear to engage selectively with 
peroxisomes based on our proteomic profiling (Supplementary 
Fig. 7e,f). Astrocytic mitochondria performed significantly better 
than PC-derived mitochondria in coupling efficiency (CE; A versus 
PC: 1.2-fold; P = 0.03, one-tailed Welch’s t-test; n = 11 and 10 iso-
lations), respiratory capacity ratio (RCR: 1.6-fold; P < 0.001; n = 11 
and 9 isolations) and spare capacity ratio (SCR: 1.7-fold; P < 0.001; 
n = 9 isolations). In contrast, selective respiration via complex I and 
II did not differ significantly (Fig. 5d,e and Supplementary Fig. 16).
Mcu mediates calcium uptake in granule cell mitochondria in 
contrast with Purkinje cells. Mitochondrial calcium influx is 
mediated via the long-elusive channel Mcu27,28 and its interactors. 
Strikingly, this pathway seems nonessential for cellular survival 
based on global Mcu deletion in outbred CD1 mice, whereas on 
inbred C57BL/6 background deletion is lethal36. Furthermore, cer-
tain tissues differentially regulate Mcu function37. We were therefore 
intrigued to find in our proteomic profiling that GC abundantly 
express the Mcu complex (Fig. 6a), whereas its protein levels are 
comparably lower in astrocytes and especially PC. We evaluated this 
by immunofluorescence stainings (Fig. 6b) and western blot analy-
sis (Fig. 6c), and found a reduction of Mcu levels to 31.7% in PC and 
45.4% in astrocytic mitochondria compared with GC mitochon-
dria. Given these differences, we analyzed calcium uptake capac-
ity of isolated, cell-type-specific mitochondria (Fig. 6d,e). Whereas 
GC mitochondria efficiently buffered calcium in a Mcu-dependent 
manner (that is, Ru360 sensitive), PC mitochondria showed a sig-
nificantly (Fig. 6e; P = 0.0018) reduced calcium buffering capacity 
(GC versus PC: P = 0.0018, analysis of variance (ANOVA) with post 
hoc testing; n = 5 and 7 isolations). Cell-type-specific ablation of 
Mcu in GC (Fig. 6f,g) abolished their mitochondrial calcium uptake 
capacity (Fig. 6h,i). Once more, these data demonstrate the diver-
sity of mitochondria even for fundamental functions and between 
neuronal subtypes, and underscore the potential of the MitoTag 
approach to analyze mitochondrial functions and signaling path-
ways in the context of individual cell types.
Rmdn3 mediates ER–mitochondria juxtapositions in Purkinje 
cells. A central aspect of mitochondrial function is communication 
with other organelles, for example, via contact sites38. Rmdn3 is an 
established tether between the ER and mitochondria involved in 
calcium29 and lipid transfer30. In our proteomic profiling, we found 
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Fig. 4 | Cell-type-specific mitochondrial markers are conserved within the CNS and across species, and they enable mitochondrial studies under pathological 
conditions. a, Cell-type-specific mitochondrial markers are conserved across the cortex (Ctx) and spinal cord (SC) as shown for Sfxn5 (astrocytic), Ociad2 
(neuronal subtype) and Nipsnap1 (neuronal) using tissue from MitoTag mice crossed to Gfap:Cre, Rbp4:Cre and ChAT:Cre-driver lines (see Supplementary 
Fig. 12), and also in corresponding human tissue (right panels within tissue group; see Supplementary Fig. 15). b–e, Mitochondrial markers in murine disease 
models and postmortem tissue from patients with Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). b, Around amyloid plaques (Hoechst, 
cyan), astrocytic mitochondria (Sfxn5, green) are excluded from the core region (white line), whereas neuronal mitochondria (Ociad2, magenta) show an 
altered density within diffuse parts of the plaques (dashed line; see Supplementary Fig. 13a). c, Postmortem cortex and hippocampus tissues from patients 
with AD confirm the distribution changes seen in mouse (see Supplementary Fig. 13c). Amyloid plaques are stained with amyloid-β antibody, and the channel 
was merged with DAPI (Nuc). d, In presymptomatic SOD1G93A mice, neuronal mitochondria (Mcu, magenta) are morphologically altered, whereas astrocytic 
mitochondria (Sfxn5, green) appear normal (see Supplementary Fig. 14a). e, In human postmortem ALS spinal cord, similar mitochondrial phenotypes are 
observed in remaining neurons (Nipsnap1; see Supplementary Fig. 14b; cell outline constructed from z-stack). Data from mouse tissue are representative of 
n = 2 independent experiments. Data from human tissue are representative of one experiment performed in n ≥ 3 cases. Case identifiers are given after disease 
names. Scale bars: 20 µm (a–e) (5 µm in insets). 9M/3M, 9 months and 3 months; ChAT, choline acetyltransferase; Nuc, nuclear counterstain.
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this OMM protein39 to be enriched in PC mitochondria by 3.5-fold 
over GC mitochondria and 4.1-fold over astrocytic mitochondria. 
Previous reports established the interaction of Rmdn3 with ER–
membrane proteins, namely VAPB (an amyotrophic lateral sclero-
sis-associated protein)29 and ORP5/8 (ref. 30). First, we confirmed 
by immunofluorescence staining that Rmdn3 is highly enriched in 
PC mitochondria (Fig. 7a). Next, we tested the functional predic-
tion that PC possess more extensive ER–mitochondria contacts 
compared with GC and astrocytes. Indeed, using ultrastructural 
analysis, we found that organelle contacts in PC somata were 6.2-
fold more enriched compared with GC somata and 2.6-fold more 
extensive compared with neighboring astrocytes (contacts ≤ 30 nm 
in distance: 37.7% PC versus 6.1% GC/14.5% astrocytes; in all cases, 
P < 0.0001, Kruskal–Wallis with post hoc testing; n = 160, 134 and 
120 mitochondria from two mice; Fig. 7b and Supplementary Fig. 
17a). Finally, using a knockout mouse model, we confirmed that 
these juxtapositions are affected by Rmdn3 levels. These mice 
showed a gene dose-dependent protein loss in cerebellum by 
western blot and immunofluorescence analysis (Fig. 7c,d), even 
though some nonspecific bands and residual nonneuronal staining 
persisted. Ultrastructural appraisal demonstrated a reduction of 
ER–mitochondria contacts in PC somata (contacts ≤30 nm in 
distance: +/+, 37.1%; +/−, 28.3%; −/−, 19.6%; +/+ versus −/−: 
P < 0.0001, +/+ versus +/−: P = 0.0022, +/− versus −/−: P = 0.0016, 
ANOVA with post hoc testing; n = 12, 8 and 14 cells from two to 
three mice; Fig. 7e and Supplementary Fig. 17b), whereas contacts 
in astrocytes were not significantly altered.
Discussion
Here, we describe a versatile approach to obtain intact cell-type-
specific mitochondria from complex tissues. This approach allows 
for functional and ‘omics’-level analysis of mitochondria derived 
from any cell type during development, physiology and disease. We 
demonstrate this by comparing the mitochondrial proteomes of the 
principal inhibitory and excitatory neurons, as well as of the major 
glial cell type in the mouse cerebellum.
Compared with other methods that explore the molecular com-
position of mitochondria, our approach has a number of advan-
tages. First, mice of all ages and genotypes can be used, enabling 
studies of aging-related changes or disease models, which for many 
cell types are not possible with cell culture- or tissue dissociation-































































































Fig. 5 | Astrocytic mitochondria metabolize long-chain fatty acids more efficiently than neurons. a, Localization of the three steps of beta-oxidation in 
mitochondria: fatty acid (FA) import (1), initial breakdown (2) and final breakdown (3). Heat map showing cell-type-specific protein changes for enzymes 
involved in beta-oxidation as average log2 FC (IC GFP/IC Tom). b, Immunostaining for Cpt1a (magenta) colocalizes with astrocytic mitochondria in the 
cerebellum (right; Gfap:Cre/GFP–OMM, green). Staining is additionally shown in tissue from Cre−, L7:Cre/GFP–OMM and Gabra6:Cre/GFP–OMM mice. 
Hash sign (#) indicates nuclear signal of Cpt1a. Images show representative results from n = 3 independent experiments. c–e, Bioenergetic parameters 
derived from oxygen consumption measurements of immunocaptured mitochondria from PC (L7:Cre/GFP–OMM) or astrocytes (Gfap:Cre/GFP–OMM) 
in the presence of different substrates. c, All parameters under palmitoyl–carnitine/malate are significantly higher in astrocytic mitochondria (CE: 
P = 0.0436; RCR: P = 0.0001; SRC: P < 0.0001, one-tailed, unpaired Welch’s t-test; n ≥ 9 isolations). d,e, Parameters under pyruvate–malate (d) and 
succinate–rotenone (e) do not show any significant difference. For comparison, parameters are normalized to corresponding IC Tom value (gray bars; see 
Supplementary Fig. 16 for non-normalized values). Dot plot: mean ± s.e.m. Scale bars: 25 µm (c) (5 µm in insets). CE, coupling efficiency; RCR, respiratory 
capacity ratio; SCR, spare capacity ratio. 
































































































































































Fig. 6 | Granule cell mitochondria robustly buffer calcium via Mcu in contrast with Purkinje cell mitochondria. a, Heat map showing cell-type-specific 
protein changes for known components of the Mcu complex as average log2 FC (IC GFP/ IC Tom). b, Immunostaining for Mcu (magenta) colocalizes 
with GC mitochondria in the cerebellum (middle; Gabra6:Cre/GFP–OMM, green). Staining is additionally shown in tissue from L7:Cre/GFP–OMM and 
Gabra6:Cre/GFP–OMM mice. c, Validation of Mcu levels in mitochondria from PC, GC and astrocytes (A) using western blot analysis. Cell-type-specific 
mitochondria (IC GFP) were analyzed probing for Mcu, Emre and ATP5a. Graphs show quantification of Mcu levels relative to mitochondrial content  
(PC versus GC: P = 0.0047, one-way Friedman’s test with post hoc testing; n = 5 experiments from four mice per group). d, Calcium uptake of 
immunocaptured mitochondria from the three cell types in the absence (black line) or presence (blue line) of Ru360, an Mcu inhibitor. Calcium uptake is 
shown as the decrease in fluorescence of the extra-mitochondrial calcium indicator GaGreen-5N after the application of 20 µM CaCl2. Traces are from one 
experiment performed with all cell types and quantified in e. Mito, mitochondria. e, Quantification of calcium uptake shown in d is related to the first pulse 
of CaCl2, given as ΔAUC/AUCRu360 (GC versus PC: P = 0.0018, ANOVA with post hoc testing; n ≥ 5 isolations). Datasets of GC mitochondria and +/+ 
mitochondria in i are identical. f, Validation of Mcu knockout in mitochondria from GC (Gabra6:Cre/GFP–OMM × McuFL/FL) using western blot analysis. 
GC-specific mitochondria (IC GFP) were analyzed probing for Mcu, Emre and ATP5a. Graphs show quantification of Mcu levels relative to mitochondrial 
content (P < 0.0001 for all comparisons, one-way restricted maximum likelihood (REML) with post hoc testing; n = 6–10 mice). g, Immunostaining for Mcu 
(magenta) in Gabra6:Cre/GFP–OMM × McuFL/FL background shows depletion of Mcu signal in GFP–OMM-labeled GC mitochondria (right). Other cell 
types are not affected and show Mcu expression. h, Calcium uptake of immunocaptured mitochondria from GCs deficient in Mcu (+/+, +/− and −/−) in 
the absence (black line) or presence (blue line) of Ru360 with application of 20 µM CaCl2. Traces are from one experiment performed with all genotypes 
and quantified in i. i, Quantification of calcium uptake related to the first pulse of CaCl2 given as ΔAUC/AUCRu360 (+/+ versus −/−: P < 0.0001; +/− 
versus −/−: P < 0.0001, one-way ANOVA with post hoc testing; n ≥ 5 isolation). Datasets of +/+ mitochondria and GC mitochondria in e are identical. 
Dot plot: mean ± s.e.m.; box plot: median, quartile 1–quartile 3, maximum and minimum values. Images in b and g show representative results from n = 3 
independent experiments. Scale bars: 25 µm (b,g) (5 µm in insets).
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mitochondria from all compartments can be obtained. We illustrate 
this by capturing axonal mitochondria from cholinergic forebrain 
projections (Supplementary Figs. 1b and 5d). Importantly, the sys-
tematic exploration of compartment-specific mitochondria is pos-
sible with the MitoTag approach, for example, from neurons that 
project to different brain regions. Although still in its infancy, this 
research area will probably yield fundamental insights into the mul-
tifaceted role of neuronal mitochondria3 given the recent insights 
into the role of local translation for mitochondrial homeostasis at 
synapses and in axons40, as well as into compartment-specific regu-
lation of mitochondrial dynamics41. Third, whereas transcriptomes 
allow exploring the regulation of mitochondrial gene expression35, 
mitochondrial proteomes are shaped by several layers of regula-
tion3 and hence are even less predictable from transcriptomes than 
global cellular proteomes9. Our direct proteomic approach circum-
vents this limitation. Fourth, our approach can yield proteins that 
are uncharacterized or only transiently associated with mitochon-
dria that would be otherwise overlooked by methods relying on 
prior knowledge of mitochondrial localization. Fifth, in contrast 
with methods that are based on the affinity purification of labeled 
proteins from cell types, for example, BONCAT42 or APEX43, our 
approach provides the intact and functional organelle for correlated 






























































































































Fig. 7 | Rmdn3 mediates close eR–mitochondria juxtapositions in  
Purkinje cells. a, Immunostaining for Rmdn3 (magenta) colocalizes with 
PC mitochondria in the mouse cerebellum (second panels from left; 
L7:Cre/GFP–OMM, green). Staining is additionally shown in tissue from 
Cre−, Gfap:Cre/GFP–OMM and Gabra6:Cre/GFP–OMM mice. Images 
show representative results from n = 3 independent experiments.  
b, Ultrastructural analysis of ER–mitochondria (mito) proximity in wild-type 
cerebellum reveals the degree of proximity of ER (orange) to mitochondria 
(magenta) in the cytoplasm of PC, GC and adjoining astrocytes. Note 
differing scale bar sizes because of mitochondrial size. The contact 
frequency between organelles is shown as % mitochondrial perimeter in 
distance ≤ 30 nm (red lines) and illustrated as box plot (median, quartile 
1–quartile 3, maximum and minimum values; black) using cells per cell 
type (n = 10, 74 and 16 cells from two mice; increased n for GC because of 
cell morphology) and as box plot (median, quartile 1–quartile 3, maximum 
and minimum values; magenta) using mitochondria as statistical entities 
(P < 0.0001 in all comparisons, one-way Kruskal–Wallis test with post hoc 
testing; n ≥ 120 mitochondria per cell type from two mice). c,d, Rmdn3- 
knockout mice show a gene dose-dependent reduction in Rmdn3 protein 
levels in the cerebellum. c, Total lysate from the cerebellum of wild-type 
(+/+), heterozygous (+/−) and knockout (−/−) mice was analyzed 
via western blot probing for Rmdn3 (size: 51 kDa and > 130 kDa) and 
mitochondrial proteins (ATP5a, CypD). Graphs (mean ± s.e.m. with 
individual points) show quantification of Rmdn3 levels relative to 
mitochondrial content (+/+ versus −/−: P = 0.0001, +/+ versus +/−: 
P = 0.0005, two-tailed, paired t-test; n = 4 mice). d, Immunostaining for 
Rmdn3 (magenta) in wild-type (left; +/+) and knockout (right; −/−) 
cerebellum shows loss of mitochondrial pattern in PC. The weak residual 
signal in astrocytic mitochondria is because of imperfect specificity of the 
antibody for the canonical form (52 kDa) of Rmdn3 (see Supplementary 
Fig. 18c). Images show representative results from n = 2 independent 
experiments. e, Ultrastructural analysis of ER–mitochondria proximity  
in Rmdn3-knockout cerebellum reveals reduced contact frequency  
(ER, orange; mitochondria, magenta; contact, red lines) in the cytoplasm 
of PC (electron micrograph). Box plot (median, quartile 1–quartile 3, 
maximum and minimum values; gray tones) shows the decrease in contact  
frequency between organelles based on cells as statistical entities (≤ 30 nm 
distance; +/+ versus −/−: P < 0.0001, +/+ versus +/−: P = 0.0022,  
+/− versus −/−: P = 0.0016, one-way ANOVA with post hoc testing; n ≥ 8 
cells from two to three mice) in PC, but not in astrocytes (+/+ versus −/−: 
P = 0.17, +/+ versus +/−: P = 0.12; n ≥ 10 cells from 2–3 mice) and box plot 
(median, quartile 1–quartile 3, maximum and minimum values; magenta) 
shows the population of mitochondria per genotype and cell type (n ≥ 105 
mitochondria from two to three mice). Scale bars: 25 µm (a) (5 µm in 
insets); 200 nm (b,e); 20 µm (d). Nuc, nuclear counterstain. 
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of mitochondrial functions, for example, respiration, calcium han-
dling, ROS production or metabolism44. This is further aided by 
the fluorescent tag, which allows in situ observation, and the bulk 
immunocapture approach, which is relatively swift and gentle, an 
important feature for functional investigations11. Indeed, during 
revision of this article, a metabolomic analysis of hepatocytes from 
mouse liver was reported using a related approach44.
When applied to the adult cerebellum, our approach yielded 
a number of insights. First, it revealed profound mitochondrial 
diversity among cell types, with a substantial part of the annotated 
mitochondrial proteome (∼15%) being differentially regulated 
among the investigated cell types (Fig. 3b). Second, our verified 
cell-type-specific mitochondrial proteins provided a set of in situ 
markers to characterize the distribution and morphology of mito-
chondria in specific neural cell types across developmental stages 
and brain regions. Third, these markers allow resolving of cell-
type-specific mitochondrial changes under pathological condi-
tions, both in mouse models and human tissue, because of their 
conservation across species (Supplementary Fig. 15). Especially 
in human tissue, this has only been possible for cellular compart-
ments that are large enough to be resolved by light microscopy45, 
or by using electron microscopy, which is cumbersome and highly 
susceptible to postmortem changes. We highlight this applica-
tion by demonstrating mitochondrial morphology in neurons 
and astrocytes around amyloid-β plaques in APPPS1 mice and 
in the spinal cord of SOD1G93A mice, as well as in corresponding 
human autopsy specimen (Fig. 4b–e). Fourth, pathway analysis 
of our cerebellar proteomes resulted in clear predictions for dif-
ferentially regulated metabolic pathways (Supplementary Fig. 7e), 
which we could directly confirm by demonstrating efficient beta-
oxidation in immunocaptured astrocytic mitochondria (Fig. 5c). 
Fifth, chiming with the astrocyte’s ability to respire on fatty acids, 
we observed an enrichment of peroxisomal proteins in immuno-
captured mitochondria from astrocytes (Supplementary Fig. 7e,f). 
Because peroxisomes are another important compartment for lipid 
metabolism and engage intimately with mitochondria, this interac-
tion might enhance glial use of lipids and the exchange of proteins 
between mitochondria and peroxisomes, for example, as part of 
peroxisome biogenesis46. Sixth, our proteomic profiling predicted 
candidates that mediate cell-type-specific regulation of organelle 
contacts. For instance, we found a recently identified mitochon-
dria-peroxisome tether, Pex11B (ref. 25), enriched in astrocytic 
mitochondria. Similarly, we identified Rmdn3 enriched in PC 
mitochondria, which mediates ER–mitochondria contact sites 
(Fig. 7). Seventh, the enrichment of Rmdn3 fits well with independent 
observations, indicating unique intracellular calcium handling 
mechanisms in PC related to this cell’s distinct morphology, fir-
ing pattern and synaptic plasticity47. In contrast, mitochondrial cal-
cium handling in GC seems to be enhanced by strong expression 
of the Mcu complex. Indeed, ex vivo comparison of mitochondria 
from these two neuronal subtypes demonstrated a robust difference 
in this fundamental calcium entry path (Fig. 6). Other cell-type-
specific regulation of mitochondrial calcium handling has been 
observed in excitable tissues28,48, regulated either by tissue-specific 
expression of Mcu components (Micu1–3) or by posttranslational 
modifications (for example, redox state)49. The low expression 
of the Mcu complex in PC thus matches intriguingly well to the 
enhanced ER–mitochondria contacts mediated by Rmdn3, but 
could also relate to the high levels of cytoplasmic calcium buffers 
in PC, for example, parvalbumin which in other cells antagonize 
Mcu expression50.
Overall, our data reveal a hitherto unappreciated cell-type- 
specific regulation of even basic mitochondrial functions in the 
CNS. Thus, this approach clearly demonstrates that cell-type- 
specific molecular diversity of mitochondria not only serves homeo-
static needs to preserve essential functions in cells of different 
geometries3, but this diversity also imbues mitochondria with 
special properties that contribute to the unique function of a 
given cell type in the healthy brain and its selective vulnerability 
during disease. Our data prove that underneath the initial percep-
tion of mitochondria as rather uniform and autonomous organelles 
lies a layer of profound cell-type-specific mitochondrial biology 
that we are only starting to appreciate. Given the startling tissue 
and cell type specificity of many pathologies involving mitochon-
dria51 and the increasing number of roles ascribed to mitochondria 
as a signaling hub, the MitoTag approach provides a valuable tool 
to recognize mitochondria fully as the multifaceted organelles that 
they are.
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Methods
Molecular cloning of GFP–OMM targeting vector for MitoTag mouse 
generation. The GFP–OMM sequence was derived from the pMXs-IP GFP–Omp25 
plasmid, which was a gift from Noboru Mizushima (Addgene plasmid 38249)52. The 
37 C-terminal amino acids of Omp25 (also known as Synj2bp) localize GFP to the 
OMM (GFP–OMM)53. The donor vector was created by obtaining the GFP–OMM 
coding sequence via NotI digestion and inserting it via blunt-end cloning into the 
expression vector pEx-CAG-stop-bpA, which was digested with BglI.
Animals. MitoTag knock-in mice were generated by recombinase-mediated 
cassette exchange into the Rosa26 locus of mouse embryonic stem cells as described 
previously54,55. In brief, the donor vector flanked by a pair of phiC31 integrase attB 
recognition sites was co-electroporated with C31-integrase expression vector into 
IDG 3.2 embryonic stem cells that harbor a pair of phiC31 integrase attP sites 
within one allele of the acceptor locus. By phiC31-mediated recombination of attB 
and attP sites, a single copy of the GFP–OMM cassette was integrated into the 
Rosa26 locus. A neomycin resistance gene located upstream of the cytomegalovirus 
early enhancer–chicken β-actin promoter enables the selection of recombined 
embryonic stem cells. These were first selected with G418 (140 µg ml−1) for 1 
week; then resistant colonies were isolated and analyzed for correct cassette 
exchange by Southern blot analysis as described previously54,56. Screened cells 
were injected into C57BL/6 blastocysts. The obtained chimeras were identified by 
PCR using the primers (5′–3′) GTTGTGCCCAGTCATAGCCGAATAG-3 and 
CACGCTTCAAAAGCGCACGTCTG (PCR product 280 base pairs (bp)), and 
further bred to C57BL/6 mice. Genotyping of MitoTag mice was performed with the 
following primers (5′–3′), which distinguish homozygous (PCR product 604 bp) and 
heterozygous (PCR product 604 and 324 bp) mice: GCACTTGCTCTCCCAAAGTC, 
CATAGTCTAACTCGCGACACTG, AGATCCGCCACAACATCG and 
TCTCACGAAGGCCCAAAC. The MitoTag mouse line is available from The 
Jackson Laboratory as JAX#032675 (Rosa26–CAG–LSL–GFP–OMM).
Thy1:mito-RFP mice57 were used to measure mitochondrial transport and 
shape in ChAT:Cre/GFP–OMM crossings (Supplementary Fig. 2a,b). In these 
transgenic mice, tagRFP is localized to the mitochondrial matrix and expressed in 
many neurons via the Thy1 promoter. In addition, tissue was used for expansion 
microscopy (matrix label; Fig. 1d) and to evaluate the immunocapture protocol via 
‘spike-in’ experiments (Fig. 2 and Supplementary Fig. 5a–c).
To express GFP–OMM in different cell types, we used the following Cre-driver 
lines: Emx1:Cre (neural cells in the forebrain; #005628; The Jackson Laboratory)58; 
ChAT:Cre (cholinergic neurons; #006410B6; The Jackson Laboratory)59, L7:Cre 
(PC; #004146; The Jackson Laboratory)60, Gabra6:Cre (cerebellar GC; gift of U. 
Fünfschilling and K.A. Nave, MPI Goettingen)61, Gfap:Cre (astrocytes; #024098; 
The Jackson Laboratory)62 and Rbp4:Cre (principle neurons layer 5/6; 031125-
UCD; Mutant Mouse Resource and Research Center (MMRRC))63,64.
To probe mitochondrial morphology in disease models, we used transgenic 
APPPS1 (ref. 65) and SOD1G93A (#004435; The Jackson Laboratory)66 mice, with the 
age of 9 months and the age range of 2–5 months, respectively. Transgenic APPPS1 
mice express mutant amyloid precursor protein KM670/671NL (Swedish) and 
mutant Presenilin 1 G384A from humans driven by the Thy1 promoter.
The Mcu knockout-first allele mouse strain was obtained from MMRRC 
(C57BL/6N-Mcutm1a(EUCOMM)Hmgu/H). To generate the conditional 
McuFL/FL mouse line, we bred Mcutm1a mice with ACTB-FLPe mice (FLP-Deleter: 
#019100; The Jackson Laboratory)67 and tested cassette removal via PCR. Mice 
were further bred with Gabra6:Cre mice to obtain GC-specific Mcu knockout 
animals. Mice were genotyped by PCR using the following primer (5′–3′): 
TGGGTGTTGATTACAAAGTTTTCA, GGTTGTCCTCTGACCTCCAC 
and GAACTTCGGAATAGGAACTTCG (PCR product 300 bp for wild-type, 
462/118 bp for mutant allele). Disruption of the endogenous locus was confirmed 
by western blot analysis and immunofluorescence staining (Fig. 6f,g). Although 
no homozygous Mcutm1a mice were born, the GC-specific deletion of Mcu did not 
cause obvious behavioral phenotype up to 6 months of age.
The Rmdn3 knockout-first allele mouse strain was created from 
embryonic stem cell clone EPD0131_4_D01, obtained from the KOMP 
Repository (https://www.komp.org) and generated by the Wellcome Trust 
Sanger Institute68. Targeting vectors used were generated by the Wellcome 
Trust Sanger Institute and the Children’s Hospital Oakland Research 
Institute as part of the Knockout Mouse Project (3U01HG004080). 
Mice were genotyped by PCR using the following primer (5′–3′): 
GCCTCAGCAGCGAGTACTTTTAC, GGTCTATGTAACTCCAGCCGTCTGG 
and GGGATCTCATGCTGGAGTTCTTCG (PCR product 231 bp for wild-type 
and 546 bp for mutant allele). Disruption of the endogenous locus was confirmed 
by western blot analysis and immunofluorescence staining (Fig. 7c,d). Loss of 
Rmdn3 caused no obvious behavioral phenotype up to 3 months of age.
All animal experiments were approved by the responsible regulatory agencies 
(Regierung von Oberbayern). If not mentioned otherwise, male and female 
animals of the species Mus musculus–C57BL/6 (mixed N/J) background were used 
within the age range of 6 weeks to 6 months.
Neonatal virus injection to deliver Cre. To excise the stop-cassette in MitoTag 
mice via adeno-associated viral delivery of Cre, we performed neonatal injections 
as described by Brill et al.69. A volume of 3 µl AAV9-hSyn-iCre (codon-improved 
Cre under the human synapsin promoter; titer: 8.494e13 ml−1; Penn Vector Core) 
was injected to achieve GFP–OMM expression in neurons (Supplementary Fig. 1f).
Imaging of axonal transport and neuromuscular health assessment. To asses 
mitochondrial transport and shape, we crossed ChAT:Cre/GFP–OMM mice to 
Thy1:mito-RFP mice and compared Cre+ and Cre− littermates. Evaluation of 
transport and shape was exclusively based on mito-RFP and GFP–OMM and used 
to confirm genotype.
Triangularis sterni explants were isolated from adult mice as previously 
described45,70. In brief, the rib cage was explanted postmortem (including the 
triangularis sterni muscle and its innervating intercostal nerves) and transferred into 
a dish with oxygenated Ringer’s solution containing (in mM): 125 NaCl, 2.5 KCl, 1.25 
NaH2PO4, 26 NaHCO3, 2 CaCl2, 1 MgCl2 and 20 glucose. Extraneous tissues were 
removed, and the explant was pinned into a Sylgard-coated 35 mm dish using insect 
pins, super-fused with warm oxygenated Ringer’s solution and kept heated at 33–35 °C 
during the whole imaging session. Mitochondrial transport in the intercostal nerves 
was assessed using an Olympus BX51WI epifluorescence microscope equipped with 
×20/0.5 numerical aperture (N.A.) and ×100/1.0 N.A. water immersion objectives, 
an automated filter wheel (Sutter) and a cooled CCD camera (Retiga EXi; Qimaging), 
controlled by µManager (v1.48; https://micro-manager.org). Neutral density filters 
were used to minimize phototoxicity and bleaching.
To assess neuromuscular synapse structure, we fixed triangularis sterni muscles 
on ice for 1 h in 4% paraformaldehyde (PFA)/PBS and stained them overnight at 
4 °C with α-bungarotoxin/biotin-XX conjugate (50 mg μl−1 diluted 1:50 in PBS; 
Invitrogen) to visualize acetylcholine receptors and Alexa Fluor 647-conjugated 
phalloidin (200 U ml−1 methanol, diluted 1:50 in PBS; Invitrogen) to visualize 
muscle fibers. The sample was subsequently incubated in a streptavidin–Alexa 
Fluor 405 conjugate (Invitrogen) for 1 h at room temperature. The area of 
neuromuscular junctions was determined using ImageJ/Fiji software71 by 
thresholding (‘Otsu’ algorithm) the α-bungarotoxin staining. Intensity was 
determined within the thresholded area with background subtraction.
Mitochondrial isolation and immunocapture protocol. Mitochondria were 
isolated from freshly collected mouse tissue as described by Wettmarshausen and 
Perocchi72. In brief, mice were anesthetized with a lethal dose of isoflurane and 
transcardially perfused with heparin (19.5 U ml−1; Sigma) in PBS. The tissue of 
interest was dissected, weighted and minced with a Dounce glass homogenizer 
using three complete up-and-down cycles of an A-type pestle in isolation buffer 
containing (in mM): 220 mannitol, 80 sucrose, 10 HEPES and 1 EDTA, pH 
7.40, and supplemented with 1% essentially fatty acid-free BSA (A7030; Sigma). 
During all steps, the sample was kept on ice or at 4 °C. Next, the cells were 
opened by nitrogen cavitation using a cell disruption vessel (model 4635–39; Parr 
Instrument Company) at 800 psi and under stirring at 60 r.p.m. for 10 min. Upon 
release from the disruption vessel, 1× protease inhibitor (cOmplete, EDTA-free 
Protease Inhibitor Cocktail; Roche) was added to the resulting total tissue fraction, 
and nuclei and debris were removed by centrifugation for 10 min at 600g. The 
supernatant was transferred and centrifuged again. The resulting postnuclear tissue 
fraction was filtered through a preseparation filter (#130-041-407; Miltenyi Biotec).
From this fraction, a volume equivalent to 20 mg initial tissue was centrifuged 
for 3 min at 12,000g, and the pellet was washed twice with isolation buffer 
without BSA to obtain the crude mitochondrial fraction (CMF). For respiratory 
measurements, the final CMF was gently resuspended in 30 µl of isolation buffer 
with 0.2% essentially fatty acid-free BSA. For western blot analysis, the pellet was 
immediately stored at −20 °C.
For immunocapture against Tom22 (refs. 15,73) or GFP–OMM, the postnuclear 
tissue fraction was diluted to a concentration of maximal 2 mg tissue ml−1 in 
immunocapture buffer (ICB) containing (in mM): 137 KCl, 2.5 MgCl2, 3 KH2PO4, 
10 HEPES, 1 EDTA, pH 7.40, and supplemented with 1% essentially fatty acid-free 
BSA and 0.5× protease inhibitor. Fifty-microliter microbeads coated with mouse 
IgG1 antibodies against Tom22 (#130-096-946; Miltenyi Biotec), GFP (#130-091-
125; Miltenyi Biotec) or CD4 (#130-047-102; Miltenyi Biotec) were added and 
incubated on a shaker (60 r.p.m.) for 30–90 min at 4 °C. Incubation was dependent 
on cell type abundance within tissue and adjusted accordingly, for example for 
cortex from Emx:Cre/GFP–OMM 30 min and for cortex from ChAT:Cre/GFP–
OMM 90 min. To separate microbead-coated mitochondria from the solution, we 
placed LS columns (#130-042-401; Miltenyi Biotec) in a magnetic QuadroMACS 
Separator (#130-090-976; Miltenyi Biotec) and equilibrated with 3 ml of ICB. 
The immunocapture was applied to the column in 3-ml steps, followed by three 
3-ml washing steps with ICB. The column was removed from the separator, and 
mitochondria were gently flushed out in 4 ml of ICB with a plunger. Mitochondria 
were pelleted by centrifugation for 3 min at 12,000g and washed twice with 
isolation buffer without BSA. For respiratory measurements, the final pellet was 
gently resuspended in 30 µl of isolation buffer with 0.2% essentially fatty acid-free 
BSA. For western blot analysis, the sample was immediately stored at −20 °C.
We deliberately avoided use of an additional Percoll gradient for further 
purification74 to preserve organelle interactions and mitochondrial integrity75.  
This results in some level of commonly known contaminations (Supplementary 
Fig. 3a,d), which, however, is largely eliminated by normalization to IC Tom, where 
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it is equally present. However, if purity is desired over organelle viability, yield and 
time, purity can be improved by a Percoll gradient after immunocapture.
Protein amount determination. Protein concentration in samples was determined 
using the BCA assay (Pierce BCA Protein Assay Kit; Thermo Fisher Scientific) 
according to the manufacturer’s instructions and using BSA as the standard. Sample 
buffer was used to correct for measurement alterations caused by detergent or BSA.
Measurement of mitochondrial respiration. The oxygen consumption rate  
(OCR) of mitochondria during respiration was measured in the assay solution 
MAS-1X containing (in mM): 70 sucrose, 220 mannitol, 10 KH2PO4, 5 MgCl2,  
2 HEPES, 1 EGTA and 0.2% essentially fatty acid-free BSA, using a Seahorse  
XFe96 Extracellular Flux Analyzer (Seahorse Bioscience). A specific amount of 
CMF or immunocaptured mitochondria was added in a volume of 10 µl to each 
well in a 96-well plate (see below for substrate details). To attach mitochondria,  
we centrifuged the plate at 2,000g, 4 °C for 20 min. Substrate mixture was added, 
and the plate was brought to equilibrium at 37 °C. Respiration was determined  
in the presence of either succinate/rotenone (10 mM/2 µM), pyruvate/malate  
(10 mM/2 mM) or palmitoyl–carnitine/malate (50 µM/2 mM)76,77 as substrates. First,  
basal measurements of OCR (state 2) were obtained. Next, adenosine diphosphate 
(ADP; 4 mM) was injected (state 3), followed by sequential injections of oligomycin 
(1.5 µM; state 4o), carbonyl cyanide m-chlorophenyl hydrazone (CCCP; see later 
concentration per substrate; state 3u) and antimycin A/rotenone (4 µM/2 µM) 
to disrupt mitochondrial respiration. Together, this injection series allowed for 
determination of ADP-uncoupled respiration (ADP), proton leak (oligomycin), 
maximal respiration (CCCP) and nonmitochondrial residual oxygen consumption 
(antimycin A/rotenone). Samples from individual isolations were run in at least 
eight technical replicates using typical mixing (1 min) and measurement cycle 
times (3 min). For each injection, technical replicates were counted only when 
there was a response to the injection and mitochondria did not detach during the 
experiment. Each state was corrected for the nonmitochondrial residual oxygen 
consumption value obtained with antimycin A/rotenone injection.
The following amounts of mitochondria and CCCP concentrations were used, 
respectively, for the indicated substrates: (1) cortical mitochondria obtained by 
differential centrifugation (CMF) of 2 µg and 10 µM for succinate/rotenone and 
pyruvate/malate; (2) cortical mitochondria obtained by immunocapture (IC) of 
1 µg and 10 µM for succinate/rotenone and 2 µg and 10 µM for pyruvate/malate; 
and (3) cerebellar mitochondria obtained by IC of 2 µg and 7.5 µM for succinate/
rotenone, 3 µg and 7.5 µM for pyruvate/malate and 8 µg and 3 µM for palmitoyl–
carnitine/malate.
Coupling efficiency (CE) was calculated as the ATP-linked OCR ((basal–
oligomycin)/basal respiration); respiratory control ratios (RCR) were calculated 
as the (ADP-linked/oligomycin OCR) readings and the spare capacity ratio (SCR) 
as the maximal respiration (CCCP driven/basal). Analysis was performed with 
Seahorse XFe96 Wave software (v.2.3.0.19.; Agilent), Microsoft Excel 2016 and 
GraphPad Prism v.7 (GraphPad Software).
Mitochondrial calcium uptake. Calcium uptake of immunocaptured 
mitochondria was performed as described by Wettmarshausen and Perocchi72 with 
the following modifications: mitochondria (50 µg) were resuspended in respiration 
buffer containing (in mM): 137 KCl, 2.5 MgCl2, 3 KH2PO4, 10 HEPES, 5 succinate, 
5 malate, 5 glutamate, 0.2% essentially fatty acid-free BSA, pH 7.4, supplemented 
with 100 nM CalciumGreen-5N (C3737; Thermo Fisher Scientific) in the absence 
or presence of 10 µM Ru360 (#557440; Sigma). Fluorescence (excitation 485/
emission 530) was measured via a microplate reader (CLARIOstar; BMG Labtech) 
in 2-s intervals for a total of 24 min with the injection of 20 µM CaCl2 in the assay 
buffer every 3 min at 25 °C.
Calcium uptake capacity was calculated as the differential area under the 
curve (ΔAUC) between the presence and absence of Mcu inhibitor Ru360. In 
brief, the first CaCl2 injection was ignored because of residual EDTA from the 
immunocapture buffer. Traces were background corrected and normalized to 
the injection time point, and AUC was calculated. Finally, the difference between 
AUC−Ru360 and AUC+Ru360 per sample is shown as percentage of AUC+Ru360. Animals 
within the age range of 8 weeks to 4 months were used from either C57BL6/mix J, 
N background or the floxed Mcu strain (Fig. 6e,i).
Western blot. For western blot analysis, material was first lysed in RIPA buffer 
containing (in mM): 50 Tris–HCl, pH 8.0, 150 NaCl, 0.1 EDTA and 1% Triton 
X-100, 0.25% Nonidet P-40, 0.1% SDS, as well as protease inhibitor (cOmplete, 
EDTA-free Protease Inhibitor Cocktail; Roche) on ice for 30 min with frequent 
vortexing. Protein concentration was determined via BCA assay; samples were 
mixed with 1× LDS sample buffer (#NP0007; Thermo Fisher Scientific) containing 
50 mM dithiothreitol (DTT) and boiled at 70 °C for 10 min. Per sample, 10 µg 
of protein was used in the case of mitochondrial isolations and whole-tissue 
comparison; 20 µg was used in the case of total cerebellar lysates to evaluate  
Rmdn3 expression (Fig. 7c). Using SDS polyacrylamide gels (12% or 4–20%), 
we separated samples via electrophoresis with Tris–glycine buffer (25 mM Tris 
base, 192 mM glycine, 0.1% SDS) and transferred on PVDF membrane (0.2 µm; 
Millipore) with Twobin buffer containing 25 mM Tris base, 192 mM glycine and  
20% methanol using the TurboBlot semidry system (Bio-Rad) with the following 
settings: 20 V maximum, 1.3 A, 12 min. After transfer, membranes were washed 
with water and air-dried, followed by SyproRuby staining (#S11791; Thermo 
Fisher Scientific) for total protein quantification according to the manufacturer’s 
instructions. SyproRuby signals were acquired using UV light on the Fusion 
FX7 machine (Vilber Lourmat). To remove total protein staining, we incubated 
membranes in 3% skim milk/TBSt (0.1% Tween 20 in TBS) for 30 min at room 
temperature and blocked them for a further 30 min in new solution. Incubation 
with primary antibody was performed overnight on a shaker (60 r.p.m.) at 4 °C 
in 3% skim milk/TBSt using the following antibodies: mouse Actin (A2228, 
Sigma; 1:4000), Ak4 (sc271161; 1:100; Santa Cruz), ATP5a (ab14748; 1:10,000; 
Abcam), CypD (ab110324; 1:5,000; Abcam), GFP (sc-9996; 1:500; Santa Cruz); 
and rabbit Calreticulin (12238; 1:1,000; Cell Signaling), Cox4i1 (AP22111a; 
1:1,000; Abgent), Emre (sc-86337; 1:500; Santa Cruz), Gldc (HPA002318; 
1:1,000; Sigma), Got2 (ab171739; 1:1,000; Abcam), Lamin B1 (ab16048; 1:1,000; 
Abcam), Mcu (HPA016480; 1:1,000; Sigma), Ociad2 (HPA040979; 1:1,000; 
Sigma), Rmdn3 (ab189845; 1:2,000; Abcam), Sfxn5 (ab172971, Abcam; 1:2,000), 
SNAP25 (5308; 1:2,000; Cell Signaling), Tomm20 (ab78547; 1:1,000; Abcam) 
and RFP (AB234, Evrogen; 1:5,000). Membranes were washed three times in 
TBSt at room temperature on a shaker (60 r.p.m.) for 10 min, followed by a 2-h 
incubation of either goat anti-mouse horseradish peroxidase (HRP) or goat anti-
rabbit HRP (1:5,000; Bio-Rad) in 3% skim milk/TBSt on a shaker (60 r.p.m.) at 
room temperature. After washing, membranes were incubated with ECL Prime 
(RPN2232s; GE Healthcare Life Sciences) according to the manufacturer’s 
instructions, and signals were acquired using the Fusion FX7 machine. A second 
round of antibody probing was performed for antibodies from a different species. 
After extensive washing in TBSt at room temperature, membranes were blocked 
again and incubated overnight with primary antibody. Cross-reactivity of 
antibodies from rabbit and mouse was excluded in prior experiments.
For quantification, samples were run as technical triplicates on one membrane, 
and the mean was further used for graphs and statistics, with the exception of 
Supplementary Fig. 5b, where sample amounts limited the analysis to one per 
experiment, and Fig. 6c,f, where samples were run as duplicates. Nonsaturated 
images were used and analyzed with Image Studio Lite software (LI-COR) and 
Microsoft Excel 2016. Signals per lane were background subtracted and normalized 
with total protein signals (SyproRuby) using dosimetry; results were expressed 
as FC to a given sample on the membrane. Mitochondrial content (evaluated by 
ATP5a, CypD and Tomm20) was further used for normalization when proteins 
were compared between different isolations. Uncropped western blots for all 
depicted blots in figures are shown in Supplementary Fig. 18.
Sample preparation for mass spectrometry. Samples for mass spectrometry were 
obtained from 8- to 9-week-old male mice. Mitochondria were immunocaptured 
from the cerebellum according to the described protocol with the alteration that 
the final mitochondrial pellet was washed twice in isolation buffer without EDTA 
and BSA. Samples were lysed in 100 µl SDT lysis buffer (4% w/v SDS, 100 mM 
DTT, 100 mM Tris–HCl, pH 7.6) by heating for 5 min at 95 °C and ultrasonication 
(Vialtweeter: six times for 30 s, 100% amplitude, 50% cycle, maximum power; 
Hielscher Ultrasonics). Debris and nondissolved material were removed by 
centrifugation for 10 min at 20,000g. Protein concentrations were estimated using 
the Pierce 660-nm assay supplemented with the ionic detergent compatibility 
reagent (Thermo Fisher Scientific) with a dilution series of bovine albumin in 
SDT buffer for calibration. An amount of 15 µg was subjected to protein digestion 
using the filter-aided sample preparation78 with small modifications. In brief, 30 
kDa Vivacon filters (Sartorius) were used. The alkylation step was followed by 
incubation with 50 U Benzonase (Sigma-Aldrich) in 50 mM Tris–HCl, pH 8 and 
1 mM MgCl2. Afterward, three washing steps with 100 µl 8 M urea in 100 mM Tris–
HCl, pH 8, were implemented. Proteins were digested for 16 h with 0.3 µg LysC 
(Promega) followed by 4-h incubation with 0.15 µg trypsin (Promega). Peptides 
were eluted into collection tubes and desalted using C18 stop-and-go extraction79. 
Samples were dried after elution by vacuum centrifugation.
Whole cerebellum samples were lysed in a modified RIPA buffer (1% Triton 
X-100, 0.5% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 5 mM EDTA, 
50 mM Tris–HCl, pH 8). Cell debris and undissolved material were removed by 
centrifugation for 10 min, at 16,000g, 4 °C. A protein amount of 20 µg was further 
diluted 1:2 with water, and MgCl2 (10 mM) was added. Afterward, 25 U Benzonase 
(Sigma-Aldrich) was added, and the DNA digestion was performed for 30 min at 
37 °C. Protein digestion was performed using filter-aided sample preparation as 
described earlier without addition of Benzonase.
Liquid chromatography–tandem mass spectrometry data acquisition. Samples 
were analyzed on an Easy nLC-1000 nano UHPLC (Thermo Fisher Scientific) 
coupled online via a Nanospray Flex electrospray ion source (Thermo Fisher 
Scientific) equipped with a column oven (Sonation) to either a Q-Exactive or a 
Q-Exactive HF mass spectrometer (Thermo Fisher Scientific). An amount of 1.3 µg 
peptides was separated on self-packed C18 columns (300 mm × 75 µm, ReproSil-
Pur 120 C18-AQ, 1.9 µm; Dr. Maisch) using a binary gradient of water (A) and 
acetonitrile (B) supplemented with 0.1% fatty acid (0 min, 2% B; 5 min, 5% B; 
185 min, 25% B; 230 min, 35% B; 250 min, 60% B).
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The dataset from PC was analyzed on a Q-Exactive MS. Full mass spectrometry 
spectra were acquired at a resolution of 70,000 (automatic gain control (AGC) 
target: 3E+6). The ten most intense peptide ions were chosen for fragmentation 
by higher-energy collisional dissociation (resolution: 17,500, isolation width: 
2 m/z, AGC target: 1E+5, normalized collision energy (NCE): 25%). A dynamic 
exclusion of 120 s was applied for fragment ion spectra acquisition. The datasets 
from the cerebellum, GC and astrocytes (A) were analyzed on a Q-Exactive HF 
MS with slightly adjusted settings. For full mass spectrometry spectra, a resolution 
of 120,000 was applied. The 15 most intense ions were chosen for fragmentation 
(resolution: 15,000, isolation width: 1.6 m/z, AGC target: 1E+5, NCE: 26%).
Liquid chromatography–tandem mass spectrometry data analysis. Peptide 
identification, label-free quantification (LFQ) and iBAQ of proteins were 
performed with MaxQuant for each dataset separately (v.1.5.4.1 for the PC 
dataset; 1.5.5.1 for the dataset from cerebellum, GC and astrocytes) using default 
settings80. In brief, a canonical database of the reviewed reference mouse proteome 
(UniProt, download: 8 June 2016; 16,798 entries) was used for database search. 
The astrocyte dataset from the cerebellum was analyzed together with data from 
astrocytic mitochondria from the cortex because both datasets (cerebellum and 
cortex) were generated in parallel from the same biological replicate. Because 
increased sample numbers increase the number of peptide identifications, this 
part was done together; however, all further data analysis steps were exclusively 
performed on cerebellar mitochondria. The false discovery rate (FDR) for both 
peptides and proteins was adjusted to less than 1% using a target and decoy 
approach (concatenated forward/reverse database). The ‘match between runs’ 
option was enabled using a time window of 2 min. LFQ required at least two ratio 
counts of unique peptides. The mass spectrometry proteomics data have been 
deposited to the ProteomeXchange Consortium via the PRIDE (ref. 81) partner 
repository with the dataset identifier: mitochondria from PC (PXD010772), from 
GC (PXD010774) and from astrocytes (PXD010781); and whole cerebellum 
(PXD013380).
Protein intensities were further analyzed in Perseus (v.1.6.1.1.)82,83. The 
bioinformatics analysis is depicted in Supplementary Fig. 6. First, protein 
identifications (IDs) from the three mass spectrometry experiments were merged 
against the reviewed reference mouse proteome including annotation from 
MitoCarta18 and LocTree3 (ref. 84) for subcellular localization. Only proteins with 
at least two unique peptides were further considered for relative quantification. 
Protein LFQ intensities were log2 transformed. Second, for relative quantification, 
the protein log2 LFQ ratios were calculated by subtracting the log2 value of IC 
Tom from IC GFP separately for each biological replicate. Next, proteins that were 
relatively quantified in less than three biological replicates were removed, leading 
to a group of 3,130 proteins that were consistently quantified in all three datasets 
from PC, GC and astrocytes (background list for over-representation analysis in 
WebGestalt)85. Finally, the log2 FC of each protein between cell types (comparisons: 
PC/GC, PC/astrocyt (PC/A) and GC/astrocyte (GC/A)) was analyzed by a two-
sided t-test (with ≥ 3 biological replicates, randomizations: 500, permutation-based 
FDR = 0.05). Proteins with log2 FC values that passed the permutation-based FDR 
criterion are marked as dark gray circles in Fig. 3c and Supplementary Fig. 7a–c. 
The scatterplot summarizing changes in PC/A versus GC/A is depicted in Fig. 3c 
and Supplementary Fig. 7d, which show the log2 FC of PC/A (x axis) and GC/A 
(y axis) for each protein that passed the FDR criterion in at least one of the two 
comparisons.
From the pairwise t-tests between cell types (Supplementary Fig. 7a–c), 
proteins were considered to be changed if their log2 FC was ≥ |1|. Thus, they were 
further analyzed for their enrichment in a specific cell type by using the online 
Venn diagram tool (http://bioinformatics.psb.ugent.be/webtools/Venn/). Here, 
18, 51 and 114 proteins were identified to be enriched in PC, GC and astrocytes, 
respectively (Fig. 3b and Supplementary Fig. 7d) using the following definitions for 
cell type specificity: ‘PC enriched’ with FC > 1 in PC/A, combination A (FC > 1 in 
PC/A and PC/GC) and combination B (FC > 1 in PC/GC only); ‘GC enriched’ with 
FC > 1 in GC/A, combination A (FC < −1 in PC/A and PC/GC, FC > 1 in GC/A), 
combination B (FC > 1 in GC/A, FC < −1 in PC/GC) and combination C (FC < −1 
in PC/GC only); and ‘A enriched’ with FC < −1 in PC/A and/or GC/A. These 
groups are color-coded in the scatterplot in Supplementary Fig. 7d comparing 
PC/A versus GC/A.
For over-representation analysis (ORA) on KEGG pathways (Supplementary 
Fig. 7e) and the biological process category of gene ontology processes (GOTerm; 
Supplementary Fig. 7f), a WEB-based Gene Set Analysis Toolkit (WebGestalt)85 
was used with the following datasets: proteins found in ≥ 3 biological replicates 
among all experiments (n = 3,130) as background against the candidates enriched 
in astrocytes (n = 114) and merged candidates found in neurons (GC enriched, PC 
enriched, shared; n = 74). Standard parameters for the enrichment analysis were 
used with the following settings: minimum number of Entrez Gene IDs in the 
category: 5; maximum number of Entrez Gene IDs in the category: 2000;  
FDR method: Benjamini–Hochberg (multiple test adjustment); and significance 
level: top 10.
To further validate enriched KEGG pathways, we used the list of shared 
proteins among the three cell types (n ≥ 3 replicates). Before filtering through 
the online tool ‘Kegg mapper’ (https://www.genome.jp/kegg/mapper.html)86, 
the average log2 FC (IC GFP/ IC Tom) values per biological replicates were 
calculated per cell type. The heat map in Fig. 5a was generated based on the KEGG 
pathway, mmu01212, and was further curated against the following criteria: strict 
involvement in beta-oxidation, annotation in MitoCarta18 and mitochondrial 
localization in the UniProt database (March 2017).
Enrichment of mitochondrial protein abundance was calculated based on iBAQ 
values87. First, the average log10 iBAQ value per protein per group of biological 
replicates was calculated for immunocaptures. Second, the average was calculated 
over all proteins annotated as mitochondrial (magenta) and nonmitochondrial 
(gray) based on MitoCarta18 and LocTree3 (ref. 84) annotations (see Supplementary 
Fig. 3c). Finally, the difference between these two groups was transformed to FC 
(linear). Similar calculations were performed on the proteomics datasets from 
whole cerebellum and the reference dataset of Percoll-purified mitochondria from 
Pagliarini et al.7
To compare the immunocapture approach with recent studies, we generated 
Venn diagrams with the online Venn diagram tool (http://bioinformatics.psb.ugent.
be/webtools/Venn/) comparing IC Tom from cerebellum with the proteomics 
dataset from cerebellar mitochondria published by Pagliarini et al.7, from whole 
cerebellum published by Sharma et al.17 and from MitoCarta (Supplementary 
Fig. 3b). For this comparison, proteins found in ≥ 9 samples of IC Tom were 
considered.
Histology and immunofluorescence staining. Animals were killed with isoflurane 
and transcardially perfused first with heparin (19.5 U ml−1; Sigma) in PBS followed 
by 4% PFA in PBS. Tissues were kept in 4% PFA/PBS overnight at 4 °C and 
subsequently cut using a vibratome (Leica).
If not mentioned differently, all staining steps were performed on a shaker 
(60 r.p.m.) at room temperature. Depending on the epitope, tissue sections were 
permeabilized with different conditions (see Supplementary Table 1), extensively 
washed, and blocked using 2% fish gelatin (Sigma), 2% FBS (Thermo Fisher 
Scientific) and 2% BSA (A7030; Sigma) in PBS for 1 h. For primary antibodies 
produced in mouse, sections were incubated with mouse Fab fragments (1:100 
in PBS; Bio-Rad) for 1 h. Incubation with primary antibody was performed in 
10% blocking/PBS solution at 4 °C overnight (see Supplementary Table 1). After 
extensive washing, secondary antibodies (1:1,000) were applied in 10% blocking/
PBS for 2 h. Tissue sections were further stained with Hoechst (Hoechst 33342; 
0.01 mg ml–1 in PBS; Molecular Probes) for 10 min and mounted using Vectashield 
mounting medium (H-1000; Vector Laboratories).
To perform double labeling of mitochondrial markers with antibodies raised 
in the same species, we used the Zenon Alexa Fluor 647 Rabbit IgG Labeling Kit 
(Z25308; Thermo Fisher Scientific) according to the manufacturer’s instructions. 
In brief, 1 µg of rabbit anti-Sfxn5 antibody (ab172971; Abcam) was linked to 10 µl 
of component A and after 5-min incubation stopped with 10 µl of component B. 
After incubation with secondary antibody and extensive washing, sections were 
incubated with Zeno complex and Hoechst for 2 h. The sections were washed three 
times in PBS for 5 min. Importantly, to stabilize staining for longer storage, we 
further incubated sections in acryloyl-X, SE, 6-((acryloyl)amino)hexanoic acid, 
succinimidyl ester (AcX; 1:100 in PBS; A20770; Thermo Fisher Scientific) for 4 h 
at 4 °C and mounted them using Vectashield mounting medium (H-1000; Vector 
Laboratories).
To visualize amyloid plaques and amyloid-β deposition in APPPS1 mice, 
we used Hoechst (Hoechst 33342; 0.01 mg ml–1 in PBS; Molecular Probes), 
which superiorly detected the entire plaque with its periphery, a feature that was 
reported for Alzheimer’s disease mouse models by Uchida and Takahashi88. We 
further confirmed amyloid-β detection using the antibody clones 4G8 (#800708; 
BioLegend) and 6E10 conjugated to Alexa Fluor 647 (#803020; BioLegend), which, 
however, penetrated less well in our staining conditions. For human tissue, the 
amyloid-β antibody clone 6F/3D (M0872; Dako) was used.
For human tissue sections the following changes for immunohistochemical 
stainings were applied (see Supplementary Table 2): after deparaffination, heat-
induced antigen retrieval was performed on PFA fixed tissue. After 10% FCS/PBS 
unspecific binding blockade, sections were incubated with primary antibodies 
in Dako Diluent (#52022; Dako) at 4 °C overnight. After extensive washing with 
Wash Buffer (#53006; Dako) and autofluorescence removal treatment (#2160; 
Merck), secondary antibodies and 4,6-diamidino-2-phenylindole (DAPI; nuclear 
counterstain, 1:2,000) were diluted in PBS and incubated at room temperature 
for 1 h. Slides were coverslipped with Fluoromount Mounting Medium (Sigma). 
For sections that require tyramide signal amplification, endogenous peroxidase 
blockade (S2023; Dako) was performed before addition of 10% FCS/PBS. After 
incubation with primary antibodies, slides were incubated at room temperature 
for 30 min with anti-rabbit HRP, followed by incubation with tyramide signal 
amplification (FP1170; Perkin Elmer) for 10 min at room temperature as a 
secondary system. Autofluorescence removal treatment was performed before 
DAPI staining. Use of human samples was in accordance with institutional ethical 
guidelines and approved by the ethics committee of the University of Geneva 
(Switzerland). Written informed consent to use autopsy samples for research 
purposes was obtained for all samples with exceptions for autopsies that were 
performed more than 20 years ago. In all cases, no samples were used from patients 
who refused involvement in research projects. Patient information is provided in 
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Supplementary Table 3. Data from human cerebellum are representative of one 
experiment; data from the human cortex and spinal cord are representative of one 
experiment performed on at least three different cases.
Fluorescence cytometry. The crude mitochondrial fraction from 20 mg cortex 
samples was resuspended in 100 µl of 4% PFA/PBS and incubated in the dark 
for 5 min at room temperature. Samples were washed three times with PBS 
and resuspended in 100 µl. Twenty microliters of fixed mitochondria was used 
per staining. First, the sample was washed once with 0.5% BSA/PBS and then 
incubated with APC-conjugated antibodies: IgG1 or Tom22 (1:25; Miltenyi Biotec) 
in the dark, 4 °C, 60 r.p.m. for 60 min. Samples were washed three times with 0.5% 
BSA/PBS and finally resuspended in 100 µl PBS. For flow cytometry, the sample 
was diluted 1:20 with PBS and analyzed using a CyAn ADP 9 flow cytometer 
(equipped with 405-, 488- and 642-nm lasers; Beckman Coulter). The flow rate was 
adjusted accordingly, and optical parameters (forward scatter (FSC) and sideward 
scatter (SSC)) were scaled logarithmically to allow for optimal identification and 
separation of small particles. Based on light-scattering properties (FSC-log versus 
SSC-log), 100,000 mitochondria were acquired per sample. Using FlowJo software 
(v.10; Tree Star), mitochondria were gated by FSC and SSC, as well as pulse width 
to discriminate doublets. Then Tom22–APC staining (APC, 665/20) intensities 
were manually gated against IgG1–APC control samples to define mitochondria. 
From this, individual gates for GFP–OMM (FITC, 530/40) and mito-RFP (PE, 
575/25) were gated according to the Cre− mitochondria. In Supplementary Fig. 
4b, values from ≥ 4 biological replicates are shown as mean ± s.e.m., as well as the 
histogram of the samples closest to mean with IgG1 control (gray histogram).
Confocal microscopy. Tissue sections were scanned either on an upright FV1000 
confocal microscopy system (Olympus) equipped with ×4/0.28 N.A. air, ×10/0.4 
N.A. air, ×20/0.85 N.A. oil, ×40/1.35 N.A. oil and ×60/1.42 N.A. oil immersion 
objectives or an inverted FV3000 confocal microscopy system (Olympus) equipped 
with ×4/0.16 N.A. air, ×20/0.75 N.A. air and ×40/0.95 N.A. air objectives. Images 
were acquired using standard filter sets, and intensity projections were generated 
using the open source software ImageJ/Fiji71 and Adobe Photoshop.
Image processing and representation. For figure representation, different 
channels of confocal image series were combined in pseudocolor using the ‘screen’ 
function in Adobe Photoshop. Contrast and brightness were equally adjusted 
across the entire image. In Supplementary Fig. 9, immunofluorescence stainings 
on Cre− tissue and control (omission of primary antibody) were acquired with 
the same settings and were adjusted with the same processing parameters. In 
nonquantitative panels, gamma was adjusted nonlinearly to enhance visibility of 
low-intensity objects. Figures were assembled in Adobe Illustrator.
Protein retention expansion microscopy. Expansion microscopy on mouse 
cortical tissue sections was performed as previously described89. In brief, the 
cerebrum of Emx1:Cre/GFP–OMMxThy1:mito-RFP mice was fixed using 4% 
PFA/PBS and sectioned in 100 µm thick sagittal section using a vibratome (Leica). 
To enhance GFP–OMM signals, we stained sections against GFP as described 
previously using 0.2% Triton X-100/PBS for permeabilization. Next, samples were 
cross-linked with acryloyl-X (AcX; 1:100 in PBS; A20770; Thermo Fisher Scientific) 
at 4 °C for 6 h, gelled with freshly prepared monomer solution (containing in g 
per 100 ml: 8.6 sodium acrylate, 2.5 acrylamide, 0.15 N,N′-methylenebisacrylamide 
and 11.7 sodium chloride in PBS) and digested with Proteinase K (8 U ml−1) at 37 °C 
overnight. For expansion, samples were first incubated in PBS and then in distilled 
water. An expansion factor of ~2- to 3-fold was estimated from the sample. Data are 
representative of n = 2 independent experiments.
Electron microscopy. Mitochondria (as crude mitochondrial fraction or 
immunocapture) were incubated in fixative containing 2.5% glutaraldehyde, 4% 
PFA, 0.1 M sodium cacodylate buffer, pH 7.2 for 10 min before being centrifuged 
and, after supernatant removal, resuspended in 2% low melting point agarose. The 
agarose mitochondria pellets were then embedded for electron microscopy using 
2% OsO4 for 4 h followed by ethanol/acetone dehydration and Epon embedding 
(Serva). To analyze mitochondrial morphology in cerebellar cells in situ, we 
perfused 2- to 3-month-old animals with 5 ml of Hank’s Balanced Salt Solution 
with heparin (19.5 U ml−1), followed by 30 ml of fixative as described. The brain 
was extracted and further postfixed for 8 h at 4 °C in fixative. Cerebella were 
dissected and sectioned in thin slices, < 1 mm. Sections were further dissected in 
pieces of two to three lobes and postfixed with 2% OsO4 and 1.5% ferrocyanide 
(Science Services), dehydrated by ethanol/acetone, and Epon embedded. Epon 
blocks were further trimmed, and 50 nm thick sections (Leica UltraCut2) were 
obtained from the thickest part of the sample. The sections were post-stained with 
4% uranylacetate for 30 min followed by lead citrate for 5 min.
For isolated mitochondria, the imaging area was performed 20–50 µm away 
from the pellet edge with a JEM-1400 Transmission Electron Microscope (Jeol 
Tokyo) using ×20,000 original magnification. Quantification for the mitochondria 
morphology in cerebellum tissue was done at ×6,000–×20,000 original magnification.
For data analysis, the investigator was blinded for the genetic background 
of samples. The open source software ImageJ/Fiji71 was used to define total 
mitochondrial perimeter and percent mitochondrial perimeter in ≤ 30 nm of 
distance to the ER. In the case of GC, a larger number of cells had to be analyzed 
because of cellular morphology. GC somata are densely packed in the GCL, with 
a small region of cytoplasm around the nucleus giving space to only one to four 
mitochondria per 50 nm section. Therefore, statistical analysis was performed on 
mitochondria as a unit (Fig. 7b).
Statistics. Datasets with groups of n < 12 are represented as dot plots with 
underlying bar graph with mean ± s.e.m. (standard error of the mean). Datasets 
with groups of n ≥ 12 are represented as box plots consisting of median, box 
spanning quartiles 1–3 (Q1–Q3) and whiskers to the maximum and minimum 
value. Data distribution was tested for normality using the Shapiro–Wilk 
normality test to determine statistical tests, and individual data points are shown 
in graphs. Exclusion of data points was performed only in oxygen consumption 
measurements for technical replicates in which one of the multiple injections failed 
during the experiment; no other data points were excluded. The statistical details 
for each experiment can be found in the figure legend, and further information 
(sample size, n of independent experiments, testing and P values) is provided in 
Supplementary Table 4. A P value < 0.05 was considered statistically significant 
and indicated by asterisks (*P < 0.05; **P < 0.01; ***P < 0.001). Statistical analyses 
were performed using Microsoft Excel 2016 and GraphPad Prism (v.7/8; GraphPad 
Software). No statistical methods were used to predetermine sample sizes, but 
the chosen sample sizes are similar to those reported in previous publications 
(for example, Brill et al.69, Baughman et al.27 and Pagliarini et al.7). Samples were 
not randomized during data collection, and mice were assigned to experimental 
groups according to genotype. Randomization was not possible due to constraints 
in animal availability and determination of experiment by given genotypes. Data 
collection and analysis were performed blind to the conditions in the following 
experiments: Figs. 1g, 7b and 7e. In all other experiments, the experimenters were 
not blinded. Further information on research design is available in the Nature 
Research Reporting Summary linked to this article and in Supplementary Table 4.
Accession codes. The mass spectrometry proteomics data have been deposited 
to the ProteomeXchange Consortium via the PRIDE partner repository with the 
dataset identifier: mitochondria from PC (PXD010772), from GC (PXD010774) 
and from astrocytes (PXD010781); and whole cerebellum (PXD013380).
Reporting Summary. Further information on the research design is available in 
the Nature Research Reporting Summary linked to this article.
Data availability
All proteomics data generated within this study are deposited to the 
ProteomeXchange Consortium via the PRIDE44 partner repository with the 
dataset identifiers PXD010772, PXD010774, PXD010781 and PXD013380. In 
addition, Supplementary Data provide information on the proteomics data analysis 
used for the conclusions in the main and supplementary figures. All additional data 
that support the findings of this study are available from the corresponding author 
upon reasonable request. The MitoTag mouse line is available from The Jackson 
Laboratory as JAX#032675 (Rosa26–CAG–LSL–GFP–OMM). The McuFL/FL and the 
Rbp4:Cre mouse strains are protected under a material transfer agreement with the 
MMRRC (C57BL/6N-Mcutm1a(EUCOMM)Hmgu/H; Tg(Rbp4-cre)KL100Gsat/
Mmucd), and the Rmdn3−/− mouse strain is protected under a material transfer 
agreement with the KOMP Repository (KO mouse project 3U01HG004080).
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A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) 
AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code
Data collection Open source software: μManager 1.48v (MM core version 8.4.0; MM studio version 1.4.22) for acquisition of mitochondrial transport; 
Seahorse XFe96 Wave, Seahorse Bioscience, Inc., (version 2.3.0.19.) for oxygen consumption measurements. 
Commercial software: for Q-Exactive Tune (2.8 SP1 build 2806) & XCalibur (version 3.1.66.10), Thermo Fisher Scientific for mass 
spectrometry; for Q-Exactive HF Tume 2.8 (SP1 build 2806) & XCalibur (version 4.0.27.19), Thermo Fisher Scientific for mass 
spectrometry; Summit software, Dako for flow cytometry; FUSION-CAPT Advance FX7, Vilber Lourmat (version 16.12) for Western blot 
development; FV10-ASW, Olympus (version 4.2) for confocal microscopy; FV31S-SW, Olympus for confocal microscopy; TEM Center, Jeol 
Tokyo for electron microscopy; CLARIOstar (software version 5.20 R5) for calcium uptake assay.
Data analysis Open source software: ImageJ/Fiji (version 1.51u) for processing of images; Seahorse XFe96 Wave, Seahorse Bioscience, Inc., (version 
2.3.0.19.) for processing of oxygen consumption measurements; GraphPad (version 7) for statistics and figure representation; Microsoft 
Excel 2016 (version 16.0.6741.2048)for statistics; Image Studio Lite, Licor (version 5.2.5) for Western blot analysis; MaxQuant (version 
1.5.1.1; version 1.5.5.1) for processing of mass spectrometry; Perseus (version 1.6.1.1.) for analysis of proteomic data and statistics. 
Open source online tools: WebGestalt 2017 (update 1/27/2017) for analysis of proteomic data; Kegg mapper (version v3.1 released 
October 1, 2017) for analysis of proteomic data; Venn diagram (http://bioinformatics.psb.ugent.be/webtools/Venn/) for figure 
representation. 
Commercial software: FlowJo software (version 10.5), TreeStar (version 10) for analysis of flow cytometry data; Adobe Photoshop CS5, 
(version 12.0) for image processing; Adobe Illustrator CS5, (version 15.0.0) for figure representation.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. 
We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
All proteomic data generated within this study are deposited to the ProteomeXchange Consortium via the PRIDE44 partner repository with the dataset identifiers: 
PXD010772, PXD010774, PXD010781 and PXD013380. Additionally, Supplementary Data Table 1 provides information on the proteomics data analysis used for the 
conclusions in the main and supplementary figures. 
The MitoTag mouse line will be available from The Jackson Laboratory as JAX#032675 (Rosa26-CAG-LSL-GFP-OMM). The McuFL/FL and the Rbp4:Cre mouse strain 
are protected under a material transfer agreement with the MMRRC (C57BL/6N-Mcutm1a(EUCOMM)Hmgu/H; Tg(Rbp4-cre)KL100Gsat/Mmucd), and the Rmdn3 -/- 
mouse strain is protected under a material transfer agreement with the KOMP Repository (KO mouse project 3U01HG004080).
Field-specific reporting
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences Behavioural & social sciences  Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size No statistical methods were used to pre-determine sample sizes but the chosen sample sizes are similar to those reported in previous 
publications (e.g. Brill et al. Neuron 2016; Baughman et al., Nature 2011 ; Pagliarini et al. Cell, 2008). 
Data exclusions Exclusion of data points was only performed in oxygen consumption measurements for technical replicates in which one of the multiple 
injections failed during the experiment; no other data points were excluded. 
Replication All attempts to replicate were successful. 
To ensure reproducibility experiments were independently repeat at least three times with the following exceptions: 
Figure 7b: data is representative for two biological replicates with N=160/133/120 mitochondria from N=10/72/16 individual cells. 
Supplementary Figure 3d: data is representative for four biological replicates with N=88/83 NMJ areas and N=56/54 AChR density 
measurements.
Randomization Samples were not randomized during data collection and animals assigned to experimental groups according to genotype. Randomization was 
not possible due to constraints in animal availability, and determination of experiment by given genotype. 
Blinding Blinding was applied to the following experiments: 
Supplementary Figure 3a: Mitochondrial transport measurements were analyzed by blinded investigator. 
Figure 1g & Supplementary Figure 3e: Isolation were performed by C.F. with information on genotype. Further oxygen consumption 
measurements and analysis were performed by L.T. in a blinded way. 
Figure 7b and 7e: Data were acquired by a blinded investigator with no information on genotypes. For analysis, it was not possible to blind the 
investigator for the different cell types (PC, GC, A) due to unique structural features.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, 
system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
Materials & experimental systems



















Antibodies used Name : Supplier , Catalog # , clone ( lot );  Dilution: 
 
Acads : Abcam , ab156571 , EPR10862(B) (lot:  GR117677-4 ); Dilution:    IF - 1: 200 ; 
Ak3 : Santa Cruz , sc-398571 , E-5 (lot:  E1616 ); Dilution:    IF - 1: 100 ; 
Ak4 : Santa Cruz , sc-271161 , A-9 (lot:  A0512 ); Dilution:  WB - 1: 100 ; IF - 1: 100 ; 
Amyloid-β (1-16)-AF647 : BioLegend , 803020 , 6E10 (lot:  B250539 ); Dilution:    IF - 1: 500 ; 
Amyloid-β (17-24) : BioLegend , 800712 , 4G8 (lot:  NaN ); Dilution:    IF - 1: 1000 ; 
Amyloid-β (8-17) : Dako , M0872 , 6F/3D (lot:  00086092 ); Dilution:    IF - 1: 100 ; 
Anti-chicken IgY-Alexa Fluor 488 : ThermoScientific , A-11039 , - (lot:  1599396, 1899514 ); Dilution:    IF - 1: 1000 ; 
Anti-chicken IgY-Alexa Fluor 647 : ThermoScientific , A-21449 , - (lot:  1622573 ); Dilution:    IF - 1: 1000 ; 
Anti-mouse IgG1-Alexa Fluor 594 : ThermoScientific , A-21125 , - (lot:  41652A ); Dilution:    IF - 1: 1000 ; 
Anti-mouse IgG-Alexa Fluor 647 : Jackson Immunoresearch , 715-605-151 , - (lot:  127051 ); Dilution:    IF - 1: 2000 ; 
Anti-mouse IgG-HRP : BioRad , 1706516 , - (lot:  NaN ); Dilution:  WB - 1: 5000 ;    
Anti-rabbit IgG-Alexa Fluor 555 : ThermoScientific , A-31572 , - (lot:  1806147 ); Dilution:    IF - 1: 2000 ; 
Anti-rabbit IgG-Alexa Fluor 568 : ThermoScientific , A-11011 , - (lot:  NaN ); Dilution:    IF - 1: 1000 ; 
Anti-rabbit IgG-Alexa Fluor 594 : ThermoScientific , A-11012 , - (lot:  1310680 ); Dilution:    IF - 1: 1000 ; 
Anti-rabbit IgG-HRP : BioRad , 1706515 , - (lot:  64170140 ); Dilution:  WB - 1: 5000 ;    
ATP5a : Abcam , ab14748 , 15H4C4 (lot:  GR303070-4 ); Dilution:  WB - 1: 10000 ; 
Beta-Actin : Sigma , A2228 , AC-74 (lot:  058M4808V ); Dilution:  WB - 1: 4000 ; 
Calreticulin : CellSignaling , #12238 , D3E6 (lot:  0004 ); Dilution:  WB - 1: 1000 ; 
Catalase : Rockland , 100-4151 , - (lot:  18043 ); Dilution:    IF - 1: 200 ; 
ChAT : Sigma , AB144P , - (lot:  3167107 ); Dilution:    IF - 1: 500 ; 
Cox4i1 : Abgent , AP22111a , RB55992 (lot:  SA160128HA ); Dilution:  WB - 1: 1000 ; IF - 1: 200 ; 
Cpt1a : ProteinTech , 15184-1-AP , - (lot:  00052905 ); Dilution:    IF - 1: 50 ; 
CypD : Abcam , ab110324 , E11AE12BD4 (lot:  GR316345-2 ); Dilution:  WB - 1: 5000 ; 
Emre (C22orf32) : Santa Curz , sc-86337 , C-12 (lot:  K0415 ); Dilution:  WB - 1: 500 ; 
Gfap : Abcam , ab4674 , - (lot:  GR1473-13 ); Dilution:    IF - 1: 2000 ; 
GFP : Abcam , ab13970 , - (lot:  GR236651-23 ); Dilution:    IF - 1: 1000 ; 
GFP : Santa Cruz , sc-9996 , B-2 (lot:  K1815 ); Dilution:  WB - 1: 500 ; 
Gldc : Sigma , HPA002318 , - (lot:  C106148 ); Dilution:  WB - 1: 1000 ; IF - 1: 400 ; 
Gls (KGA) : ProteinTech , 20170-1-AP , - (lot:  00012602 ); Dilution:    IF - 1: 200 ; 
Gls2 (C-term E513) : Abgent , AP6650d , RB20072 (lot:  SA101018BU ); Dilution:    IF - 1: 400 ; 
Got2 : Abcam , ab171739 , EPR12354(B) (lot:  GR170733-1 ); Dilution:  WB - 1: 1000 ; IF - 1: 400 (human: 1:2000) ; 
ImmPRESS® HRP Anti-Rabbit IgG (Peroxidase) Polymer Detection Kit : Vector Lab ,  MP-7451  , - (lot:  ZD0602 ); Dilution:    IF -  
ready-to-use ; 
Lamin B1 : Abcam , ab16048 , - (lot:  429044 ); Dilution:  WB - 1: 1000 ; 
Ldhd : Abcam , ab182146 , EPR15068(B) (lot:  GR152139-1 ); Dilution:    IF - 1: 100 ; 
MaoB : Santa Cruz , sc-515354 , D-6 (lot:  C0816 ); Dilution:    IF - 1: 100 ; 
Mavs : CellSignaling , #4983 , - (lot:  0003 ); Dilution:    IF - 1: 200 ; 
Mcu : Sigma , HPA016480 , - (lot:  CD114474 ); Dilution:  WB - 1: 1000 ; IF - 1: 400 (human: 1:200) ; 
Mouse IgG1-APC : Miltenyi Biotec , 130-113-758 , IS5-21F5 (lot:  NaN ); Dilution:  WB - 1: 25 ;    
NeuN : Sigma , MAB377 , A60 (lot:  2742283 ); Dilution:    IF - 1: 100 ; 
NeuN-488 : Abcam , ab190195 , EPR12763 (lot:  GR3233763-2 ); Dilution:    IF - 1: 50 ; 
Nipsnap1 : CellSignaling , #13226 , D1Y6S (lot:  0001 ); Dilution:    IF - 1: 200 ; 
Ociad2 : Sigma , HPA040979 , - (lot:  C91827 ); Dilution:  WB - 1: 1000 ; IF - 1: 200 (human: 1:500) ; 
Ociad2 : Abcam , ab91576 ,  (lot:  GR265190-2 ); Dilution:    IF - 1: 200 ; 
Pex14 : Denis Crane ;    (lot:  NaN ); Dilution:    IF - 1: 1000 ; 
Pptc7 : Abcam , ab122548 , - (lot:  GR134884-4 ); Dilution:    IF - 1: 200 ; 
Rabbit IgG zenon AlexaFluor 647 Kit : ThermoScientific , Z25308 , - (lot:  2021736 ); Dilution:    IF - 10 microl/1 microg antibody ; 
Rmdn3 (Fam82a2) : Abcam , ab189845 , - (lot:  GR26796-1 ); Dilution:  WB - 1: 2000 ; IF - 1: 400 (human: 1:2000) ; 
Sfxn5 : Abcam , ab172971 , EPR9532 (lot:  YK020618C5 ); Dilution:  WB - 1: 2000 ; IF - 1: 500 ; 
SNAP25 : CellSignaling , #5308 , D7B4 (lot:  0001 ); Dilution:  WB - 1: 2000 ;   ; 
Snph : Abcam , ab192605 , EPR14115(2) (lot:  GR300418-5 ); Dilution:    IF - 1: 200 ; 
Tom22-APC : Miltenyi Biotec , 130-107-733 , 1C9-2 (lot:  NaN ); Dilution:  WB - 1: 25 ;    
Tomm20 : Abcam , ab78547 , - (lot:  GR3199811-3 ); Dilution:  WB - 1: 1000 ;    
tRFP : Evrogen , AB234 , - (lot:  23301301013 ); Dilution:  WB - 1: 5000    ; 
Tst : Abcam , ab166625 , EPR11646(B) (lot:  YJ1120015 ); Dilution:    IF - 1: 500 (human: 1:2000) .
Validation Name ( Supplier ,  Catalog # ): Validation ; 
 
Acads ( Abcam ,  ab156571 ): Data sheet: mouse, IF; Ref: doi: 10.1111/jcmm.12828 ; 
Ak3 ( Santa Cruz ,  sc-398571 ): Data sheet: mouse, IF ; 
Ak4 ( Santa Cruz ,  sc-271161 ): Data sheet: mouse, IF ; 
Amyloid-β (1-16)-AF647 ( BioLegend , 803020 ): Data sheet: human, Tg-mouse, IF; Ref:doi: 10.1073/pnas.0813404106; PMID: 
10028915 ; 
Amyloid-β (17-24) ( BioLegend , 800712 ): Data sheet: human, Tg-mouse, IF; Ref: PMID: 10028915 ; 
Amyloid-β (8-17) ( Dako , M0872 ): Data sheet: human, IHC; Ref: PMID: 10028915 ; 
Anti-chicken IgY-Alexa Fluor 488 ( ThermoScientific ,  A-11039 ): RRID:AB_2534096; 168 citations ; 
Anti-chicken IgY-Alexa Fluor 647 ( ThermoScientific ,  A-21449 ): RRID:AB_2535866; 40 citations ; 
Anti-mouse IgG1-Alexa Fluor 594 ( ThermoScientific ,  A-21125 ): RRID:AB_2535767; 22 citations ; 
Anti-mouse IgG-Alexa Fluor 647 ( Jackson Immunoresearch , 715-605-151 ): RRID:AB_2340863; 26 citations ; 
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Anti-mouse IgG-HRP ( BioRad ,  1706516 ): RRID: AB_11125547; Ref: doi: 10.1016/j.cell.2016.07.041; WB, rat ; 
Anti-rabbit IgG-Alexa Fluor 555 ( ThermoScientific , A-31572 ): RRID:AB_162543; 115 citations ; 
Anti-rabbit IgG-Alexa Fluor 568 ( ThermoScientific ,  A-11011 ): RRID:AB_143157; 251 citations ; 
Anti-rabbit IgG-Alexa Fluor 594 ( ThermoScientific ,  A-11012 ): RRID:AB_2534079; 215 citations ; 
Anti-rabbit IgG-HRP ( BioRad ,  1706515 ): RRID:AB_2617112;  Ref: doi: 10.1016/j.cell.2016.07.041; WB, rat ; 
ATP5a ( Abcam ,  ab14748 ): Data sheet: mouse, WB; Ref: doi: 10.1111/acel.12715 ; 
Beta-Actin ( Sigma ,  A2228 ): Data sheet: mouse, WB ; 
Calreticulin ( CellSignaling ,  #12238 ): Data sheet: mouse, WB ; 
Catalase ( Rockland ,  100-4151 ): Data sheet: mouse, IF ; 
ChAT ( Sigma , AB144P ): Data sheet: mouse, WB ; 
Cox4i1 ( Abgent ,  AP22111a ): Data sheet: mouse, IF ; 
Cpt1a ( ProteinTech ,  15184-1-AP ): Data sheet: mouse, IF; Ref:doi: 10.1038/emm.2017.243 ; 
CypD ( Abcam ,  ab110324 ): Data sheet: mouse, WB; KO validation: Ref: doi: 10.1016/j.expneurol.2009.02.015 ; 
Emre (C22orf32) ( Santa Curz , sc-86337 ): Data sheet: mouse, WB; Ref: doi: 10.1016/j.celrep.2017.02.032 ; 
Gfap ( Abcam , ab4674 ): Data sheet: mouse, human, IF; Ref: doi: 10.1177/1759091415601636 ; 
GFP ( Abcam ,  ab13970 ): Data sheet: mouse, IF ; 
GFP ( Santa Cruz ,  sc-9996 ): Data sheet: mouse, WB ; 
Gldc ( Sigma ,  HPA002318 ): Data sheet: mouse, IF; siRNA KD validation ; 
Gls (KGA) ( ProteinTech ,  20170-1-AP ): Data sheet: mouse, IF; Ref:doi: 10.1038/s41598-017-16327-z ; 
Gls2 ( Abgent ,  AP6650d ): Data sheet: mouse, IF ; 
Got2 ( Abcam ,  ab171739 ): Data sheet: mouse, IF; Ref:doi: 10.1186/s13024-017-0219-3. ; 
ImmPRESS® HRP Anti-Rabbit IgG (Peroxidase) Polymer Detection Kit ( Vector Lab ,  MP-7451  ): RRID:AB_2336529; 7 citations; 
Ref: doi: 10.1172/JCI92300.; mouse, IF ; 
Lamin B1 ( Abcam ,  ab16048 ): Data sheet: mouse, WB; KO validation in cells ; 
Ldhd ( Abcam ,  ab182146 ): Data sheet: mouse; human, WB. ; 
MaoB ( Santa Cruz ,  sc-515354 ): Data sheet: mouse, IF ; 
Mavs ( CellSignaling ,  #4983 ): Data sheet: mouse, IF ; 
Mcu ( Sigma ,  HPA016480 ): Data sheet: mouse, IF; KO validation: This study ; 
Mouse IgG1-APC ( Miltenyi Biotec ,  130-113-758 ): RRID:AB_2733439; Ref: doi: 10.1016/j.ab.2009.02.040; isolation, FACS, 
mouse ; 
NeuN ( Sigma , MAB377 ): Data sheet: human, IF ; 
NeuN-488 ( Abcam , ab190195 ): Data sheet: human, IF; Ref: doi: 10.1152/ajpgi.00371.2016 ; 
Nipsnap1 ( CellSignaling ,  #13226 ): Data sheet: human, mouse, WB ; 
Ociad2 ( Sigma ,  HPA040979 ): Data sheet: human, IF; human, WB ; 
Ociad2 ( Abcam ,  ab91576 ): Data sheet: mouse, human, WB ; 
Pex14 ( Denis Crane ,  - ): Ref: doi: 10.1242/jcs.02776: mouse, WB, IF ; 
Pptc7 ( Abcam ,  ab122548 ): Data sheet: mouse, IF ; 
Rabbit IgG zenon AlexaFluor 647 Kit ( ThermoScientific ,  Z25308 ): RRID:AB_2736962; Ref: doi: 10.1128/JVI.01457-17; mouse, IF ; 
Rmdn3 (Fam82a2) ( Abcam ,  ab189845 ): Data sheet: mouse, IF; KO validation: This study ; 
Sfxn5 ( Abcam ,  ab172971 ): Data sheet: mouse, human, WB ; 
SNAP25 ( CellSignaling ,  #5308 ): Data sheet: mouse, WB ; 
Snph ( Abcam ,  ab192605 ): Data sheet: mouse, IF ; 
Tom22-APC ( Miltenyi Biotec ,  130-107-733 ): RRID:AB_2654220; Ref: doi: 10.1016/j.ab.2009.02.040; isolation, FACS, mouse ; 
Tomm20 ( Abcam ,  ab78547 ): Data sheet: human, WB, IF ; 
tRFP ( Evrogen ,  AB234 ): Data sheet: mouse, WB ; 
Tst ( Abcam ,  ab166625 ): Data sheet: mouse, IF .
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals Male and female animals of the species Mus musculus/C57BL/6 (mixed N/J) background were used between 6 weeks to 6 
month.
Wild animals Study did not involve wild animals.
Field-collected samples Study did not involve field-collected damples.
Ethics oversight All animal experiments were approved by the responsible regulatory agencies (Regierung von Oberbayern).
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Human research participants
Policy information about studies involving human research participants
Population characteristics Male and female patients, 52-91 years of age; three groups: no relevant diagnosis; Alzheimer's disease, ALS
Recruitment Tissue selected from archival autopsy material.
Ethics oversight Use of human samples was in accordance with institutional ethical guidelines and approved by the ethics committee of the 
University of Geneva (Switzerland).
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The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation The crude mitochondrial fraction (CMF) from 20 mg mouse cortex samples was resuspended in 100 μl 4% PFA/PBS and 
incubated in the dark for 5 minutes at room temperature. Samples were washed three times with PBS and resuspended in 100 
μl. 20 μl fixed mitochondria were used per staining. First the sample was washed once with 0.5% BSA/PBS and then incubated 
with APC-conjugated antibodies: IgG1 or Tom22 (Miltenyi Biotec, 1:25) in the dark, 4°C, 60 rpm for 60 minutes. Samples were 
washed three times with 0.5%BSA/PBS and finally resuspended in 100 μl PBS.
Instrument Samples were acquired on a CyAn ADP 9 flow cytometer (Beckman Coulter) with the following laser lines: 405, 488, 642 nm.
Software Data was acquired with the Summit software (Dako) and further analyzed with FlowJo, TreeStar (version 10).
Cell population abundance No sorting was performed.
Gating strategy To allow for optimal identification and separation of small particles, the flow rate was adjusted accordingly and optical 
parameters were scaled logarithmically. The gate was adjusted to exclude a PBS+BSA probe (buffer only; negative) in each 
experiment. Mitochondria were gated by FSC and SSC, as well as pulse width to discriminate doublets. 
Then Tom22-APC staining (APC, 665/20) intensities were gated against IgG1-APC control samples to define mitochondria (on 
average 34.27±1.62%). From this, individual gates for GFP-OMM (FITC, 530/40) and mito-RFP (PE, 575/25) were adjusted 
according to wild type mitochondria (Tom22+).
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
